



**Europäisches  
Patentamt**

**European  
Patent Office**

**Office européen  
des brevets**

REC'D 09 JUL 2003

WIPO

PCT

**Bescheinigung**

**Certificate**

**Attestation**

Die angehefteten Unterla-  
gen stimmen mit der  
ursprünglich eingereichten  
Fassung der auf dem näch-  
sten Blatt bezeichneten  
europäischen Patentanmel-  
dung überein.

The attached documents  
are exact copies of the  
European patent application  
described on the following  
page, as originally filed.

Les documents fixés à  
cette attestation sont  
conformes à la version  
initialement déposée de  
la demande de brevet  
européen spécifiée à la  
page suivante.

**Patentanmeldung Nr. Patent application No. Demande de brevet n°**

02100624.2

**PRIORITY  
DOCUMENT**  
SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)

Der Präsident des Europäischen Patentamts;  
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets  
p.o.

**R C van Dijk**



Anmeldung Nr:  
Application no.: 02100624.2  
Demande no:

Anmeldetag:  
Date of filing: 03.06.02  
Date de dépôt:

Anmelder/Applicant(s)/Demandeur(s):

DSM N.V.  
Het Overloon 1  
6411 TE Heerlen  
PAYS-BAS

Bezeichnung der Erfindung/Title of the invention/Titre de l'invention:  
(Falls die Bezeichnung der Erfindung nicht angegeben ist, siehe Beschreibung.  
If no title is shown please refer to the description.  
Si aucun titre n'est indiqué se référer à la description.)

NOVEL PECTINASE PEC38 AND USES THEREOF

In Anspruch genommene Priorität(en) / Priority(ies) claimed /Priorité(s)  
revendiquée(s)  
Staat/Tag/Aktenzeichen/State/Date/File no./Pays/Date/Numéro de dépôt:

Internationale Patentklassifikation/International Patent Classification/  
Classification internationale des brevets:

C12N9/00

Am Anmeldetag benannte Vertragstaaten/Contracting states designated at date of  
filing/Etats contractants désignées lors du dépôt:

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

## NOVEL PECTINASE PEC38 AND USES THEREOF

**Field of the invention**

5                   The invention relates to newly identified polynucleotide sequences comprising genes that encode novel pectinases isolated from *Aspergillus niger*. The invention features the full length nucleotide sequence of the novel gene, the cDNA sequence comprising the full length coding sequence of the novel pectinase as well as the amino acid sequence of the full-length  
10 functional protein and functional equivalents thereof. The invention also relates to methods of using these enzymes in industrial processes and methods of diagnosing fungal infections. Also included in the invention are cells transformed with a polynucleotide according to the invention and cells wherein a pectinase according to the invention is genetically modified to enhance or reduce its activity  
15 and/or level of expression.

**Background of the invention**

20                   Pectin polymers are important constituents of plant primary cell walls. They are composed of chains of 1,4-linked alpha-D-galacturonic acid and methylated derivatives thereof. Enzymes that are able to degrade the above-defined pectin polymers are called pectinases. Degradation in this respect means that at least one sugar residue or ester group has been removed from the pectin molecule. Pectinases such as polygalacturonase, pectin methylesterase, pectin  
25 lyase or pectate lyase are important for the food industry, primarily in the art of fruit and vegetable processing such as fruit juice production or wine making, where their ability to catalyse the degradation of the backbone of the pectin polymer is utilised. Another application of pectinases, in particular pectin methyl  
30 esterase, is the firming of fruit and vegetables.

35                   The seeds of leguminosae like soy beans and other types of peas also contain pectin. This pectin, however, is quite different from pectins described for fruits like apple berries etc. A large part of soybean pectin is water-insoluble. In addition soybean pectin consists mainly of xylogalacturonan and rhamnogalacturonan and contains only minor amounts of homogalacturonan. The CDTA-soluble pectic substances from soybean meal are composed of

- rhamnogalacturonan and xylogalacturonan but not homogalacturonan. Due to these structural differences soybean pectin is much more difficult to degrade by pectinases as compared to fruit pectin. Even the use of technical multi-enzyme preparations was not sufficient to degrade soybean pectin structures (Huisman, MMH; Schols, HA; Voragen, AGJ, **1999**, Enzymatic degradation of cell wall polysaccharides from soybean meal, Carbohydrate Polymers 38, 299-307, and: Ouhida, I; Pérez, JF; Gasa, J; **2002**, Soybean (glycine max) cell wall composition and availability to feed enzymes, J. Agric. Food Chem 50, 1933-1938).

- 5 An assortment of different pectin degrading enzymes is known  
10 to be present in various microorganisms such as *Aspergillus niger*.

The following is a non-exhaustive list of pectin-acting enzymes:

Enzyme	E.C. Number
exopolygalacturonase	3.2.1.67
endopolygalacturonase	3.2.1.15
pectin lyase	4.2.2.10
pectate lyase	4.2.2.2
rhamnogalacturonan hydrolase	3.2.1.x
rhamnogalacturonan lyase	4.2.2.x
rhamnogalacturonan acetylsterase	3.1.1.x
RG rhamnohydrolase	3.2.1.x
RG galacturonohydrolase	3.2.1.x
xylogalacturonan hydrolase	3.2.1.x
pectin acetylsterase	3.1.1.x
pectin methylesterase	3.1.1.11
endo-arabinase	3.2.1.99
beta-arabinofuranosidase	3.2.1.55
beta-1,4-galactanase	3.2.1.89
beta-1,3-galactanase	3.2.1.90
beta-galactosidase	3.2.1.23
alpha-galactosidase	3.2.1.22

feruloyl acetyl esterase	3.1.1.x
alpha-fucosidase	3.2.1.51
(beta-fucosidase)	3.2.1.38
beta-apiosidase	3.2.1.x
alpha-rhamnosidase	3.2.1.40
beta-rhamnosidase	3.2.1.43
alpha-arabinopyranosidase	3.2.1.x
beta-glucuronidase	3.2.1.31
(alpha-glucuronidase)	3.2.1.139
beta-xylosidase	3.2.1.37
(alpha-xylosidase)	3.2.1.x

Pectin methylesterase catalyses the removal of methanol from pectin, resulting in the formation of pectic acid (polygalacturonic acid). Pectate lyase cleaves glycosidic bonds in polygalacturonic acid by beta-elimination, pectin  
5 lyase cleaves the glycosidic bonds of highly methylated pectins by beta-elimination, and polygalacturonase hydrolyses the glycosidic linkages in the polygalacturonic acid chain.

Commercially available pectinases are actually a mixture of enzymes, which, along with other enzymes such as cellulases, are used in the  
10 fruit industry to help extract, clarify and modify fruit juices.

It is a disadvantage of these mixtures that they hardly ever contain the optimal mix of enzymes to treat a particular fruit or juice. Optimal pectin degradation depends on many factors, including the kind of fruit to be treated, the season in which the fruit is harvested, the ripeness of the fruit, and  
15 many more. A well-known example is the release of unwanted methanol and methylated pectin by the action of pectinmethylesterases and/or exo-polygalacturonases when present in too high concentrations. It is therefore an object of the present invention to provide isolated (recombinant) pectinases. The availability of isolated enzymes allows a cocktail of enzymes to be prepared  
20 which is optimized for the digestion of pectin from a particular fruit or juice.

Pectinases have been cloned in a variety of different microorganisms. Molecular cloning of pectinases in fungi has also been described. The DNA and deduced amino acid sequences of pectinases from *Aspergillus oryzae*, *Aspergillus kawachii* and *Emericella nidulans* are known.

25 However, there is still a need for other pectinases with different

properties so that fruit processing may be optimized.

One of the disadvantages of the currently available enzymes is that they have pH optima above pH 4.0. Many fruit juices are more acidic and a pH optimum below 3.8 would be desirable. Fruit juices may become as acidic as pH 2.0 and it is therefore an object of the present invention to provide pectinases with a more acidic pH optimum. Pectinases with a pH optimum below 3.8 would be especially advantageous.

Fruit processing is also often performed at more extreme temperatures. Use of pectinases with lower temperature optima would improve yield and quality of the juice because more aromas would be released. The currently available enzymes have a very low efficiency at temperatures below 15 °C. Also, at high temperatures the currently available enzymes are easily inactivated. This is a disadvantage for those fruit juices that have to be pasteurized.

The enzymes according to the invention provide a better temperature stability and can withstand more extreme temperatures in comparison with pectinases according to the prior art.

Also, the specificity of current enzymes leaves to be desired. Fruit juice that needs to be filtrated after or during processing tends to clot the filters after some time. This is due to the inability of certain enzymes to properly digest fruit polysaccharides which causes the fouling of the filters.

The present invention addresses at least one if not all of the above problems.

#### **Object of the invention**

It is an object of the invention to provide novel polynucleotides encoding novel pectinases with improved properties. A further object is to provide naturally and recombinantly produced pectinases as well as recombinant strains producing these. Also fusion polypeptides are part of the invention as well as methods of making and using the polynucleotides and polypeptides according to the invention.

#### **Summary of the invention**

The invention provides for novel polynucleotides encoding novel pectinases.

More in particular, the invention provides for polynucleotides having a nucleotide sequence that hybridises preferably under highly stringent

conditions to a sequence according to SEQ ID NO: 1 or SEQ ID NO: 2.

Consequently, the invention provides nucleic acids that are more than 40% such as about 60%, preferably 65%, more preferably 70%, even more preferably 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% homologous to the sequences

5 according to SEQ ID NO: 1 or SEQ ID NO: 2.

In a more preferred embodiment the invention provides for such an isolated polynucleotide obtainable from a filamentous fungus, in particular *A. niger* is preferred.

10 In one embodiment, the invention provides for an isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide with an amino acid sequence as shown in SEQ ID NO: 3 or functional equivalents thereof.

15 In a further preferred embodiment, the invention provides an isolated polynucleotide encoding at least one functional domain of a polypeptide according to SEQ ID NO: 3 or functional equivalents thereof.

20 In a preferred embodiment the invention provides an pectinase gene according to SEQ ID NO: 1. In another aspect the invention provides a polynucleotide, preferably a cDNA encoding an *A. niger* pectinase whose amino acid sequence is shown in SEQ ID NO: 3 or variants or fragments of that polypeptide. In a preferred embodiment the cDNA has a sequence according to SEQ ID NO: 2 or functional equivalents thereof.

25 In an even further preferred embodiment, the invention provides for a polynucleotide comprising the coding sequence of the polynucleotides according to the invention, preferred is the polynucleotide sequence of SEQ ID NO: 2.

The invention also relates to vectors comprising a polynucleotide sequence according to the invention and primers, probes and fragments that may be used to amplify or detect the DNA according to the invention.

30 In a further preferred embodiment, a vector is provided wherein the polynucleotide sequence according to the invention is functionally linked with regulatory sequences suitable for expression of the encoded amino acid sequence in a suitable host cell, such as *A. niger* or *A. oryzae*. The invention also provides methods for preparing polynucleotides and vectors according to the invention.

35 The invention also relates to recombinantly produced host cells

that contain heterologous or homologous polynucleotides according to the invention.

In another embodiment, the invention provides recombinant host cells wherein the expression of an pectinase according to the invention is  
5 significantly increased or wherein the activity of the pectinase is increased.

In another embodiment the invention provides for a recombinantly produced host cell that contains heterologous or homologous DNA according to the invention and wherein the cell is capable of producing a functional pectinase according to the invention, preferably a cell capable of over-  
10 expressing the pectinase according to the invention, for example an *Aspergillus* strain comprising an increased copy number of a gene or cDNA according to the invention.

In yet another aspect of the invention, a purified polypeptide is provided. The polypeptides according to the invention include the polypeptides  
15 encoded by the polynucleotides according to the invention. Especially preferred is a polypeptide according to SEQ ID NO: 3 or functional equivalents thereof.

Fusion proteins comprising a polypeptide according to the invention are also within the scope of the invention. The invention also provides methods of making the polypeptides according to the invention.

20 The invention also relates to the use of the pectinase according to the invention in any industrial process as described herein

### **Detailed description of the invention**

#### **25 Polynucleotides**

The present invention provides polynucleotides encoding an pectinase, tentatively called PEC38, having an amino acid sequence according to SEQ ID NO: 3 or functional equivalents thereof. The sequence of the gene encoding PEC38 was determined by sequencing a genomic clone obtained from  
30 *Aspergillus niger*. The invention provides polynucleotide sequences comprising the gene encoding the PEC38 pectinase as well as its complete cDNA sequence and its coding sequence. Accordingly, the invention relates to an isolated polynucleotide comprising the nucleotide sequence according to SEQ ID NO: 1 or SEQ ID NO: 2 or functional equivalents thereof.

35 More in particular, the invention relates to an isolated polynucleotide hybridisable under stringent conditions, preferably under highly stringent conditions, to a polynucleotide according to SEQ ID NO: 1 or SEQ ID



NO: 2. Advantageously, such polynucleotides may be obtained from filamentous fungi, in particular from *Aspergillus niger*. More specifically, the invention relates to an isolated polynucleotide having a nucleotide sequence according to SEQ ID NO: 1 or SEQ ID NO: 2.

5                   The invention also relates to an isolated polynucleotide encoding at least one functional domain of a polypeptide according to SEQ ID NO: 3 or functional equivalents thereof.

                  As used herein, the terms "gene" and "recombinant gene" refer to nucleic acid molecules which may be isolated from chromosomal DNA, which  
10               include an open reading frame encoding a protein, e.g. an *A. niger* pectinase. A gene may include coding sequences, non-coding sequences, introns and regulatory sequences. Moreover, a gene refers to an isolated nucleic acid molecule as defined herein.

                  A nucleic acid molecule of the present invention, such as a  
15               nucleic acid molecule having the nucleotide sequence of SEQ ID NO: 1 or SEQ ID NO: 2 or a functional equivalent thereof, can be isolated using standard molecular biology techniques and the sequence information provided herein. For example, using all or portion of the nucleic acid sequence of SEQ ID NO: 1 or the nucleotide sequence of SEQ ID NO: 2 as a hybridization probe, nucleic acid molecules  
20               according to the invention can be isolated using standard hybridization and cloning techniques (e. g., as described in Sambrook, J., Fritsh, E. F., and Maniatis, T. *Molecular Cloning: A Laboratory Manual*. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989).

                  Moreover, a nucleic acid molecule encompassing all or a portion  
25               of SEQ ID NO: 1 or SEQ ID NO: 2 can be isolated by the polymerase chain reaction (PCR) using synthetic oligonucleotide primers designed based upon the sequence information contained in SEQ ID NO:1 or SEQ ID NO: 2.

                  A nucleic acid of the invention can be amplified using cDNA, mRNA or alternatively, genomic DNA, as a template and appropriate  
30               oligonucleotide primers according to standard PCR amplification techniques. The nucleic acid so amplified can be cloned into an appropriate vector and characterized by DNA sequence analysis.

                  Furthermore, oligonucleotides corresponding to or hybridisable to nucleotide sequences according to the invention can be prepared by standard  
35               synthetic techniques, e. g., using an automated DNA synthesizer.

                  In a preferred embodiment, an isolated nucleic acid molecule of

the invention comprises the nucleotide sequence shown in SEQ ID NO: 2. The sequence of SEQ ID NO: 2 corresponds to the coding region of the A. niger PEC38 cDNA. This cDNA comprises sequences encoding the A. niger PEC38 polypeptide according to SEQ ID NO: 3.

5 In another preferred embodiment, an isolated nucleic acid molecule of the invention comprises a nucleic acid molecule which is a complement of the nucleotide sequence shown in SEQ ID NO:1 or SEQ ID NO: 2 or a functional equivalent of these nucleotide sequences.

10 A nucleic acid molecule which is complementary to another nucleotide sequence is one which is sufficiently complementary to the other nucleotide sequence such that it can hybridize to the other nucleotide sequence thereby forming a stable duplex.

One aspect of the invention pertains to isolated nucleic acid molecules that encode a polypeptide of the invention or a functional equivalent thereof such as a biologically active fragment or domain, as well as nucleic acid molecules sufficient for use as hybridisation probes to identify nucleic acid molecules encoding a polypeptide of the invention and fragments of such nucleic acid molecules suitable for use as PCR primers for the amplification or mutation of nucleic acid molecules.

20 An "isolated polynucleotide" or "isolated nucleic acid" is a DNA or RNA that is not immediately contiguous with both of the coding sequences with which it is immediately contiguous (one on the 5' end and one on the 3' end) in the naturally occurring genome of the organism from which it is derived. Thus, in one embodiment, an isolated nucleic acid includes some or all of the 5' non-coding  
25 (e.g., promotor) sequences that are immediately contiguous to the coding sequence. The term therefore includes, for example, a recombinant DNA that is incorporated into a vector, into an autonomously replicating plasmid or virus, or into the genomic DNA of a prokaryote or eukaryote, or which exists as a separate molecule (e.g., a cDNA or a genomic DNA fragment produced by PCR or  
30 restriction endonuclease treatment) independent of other sequences. It also includes a recombinant DNA that is part of a hybrid gene encoding an additional polypeptide that is substantially free of cellular material, viral material, or culture medium (when produced by recombinant DNA techniques), or chemical precursors or other chemicals (when chemically synthesized). Moreover, an  
35 "isolated nucleic acid fragment" is a nucleic acid fragment that is not naturally occurring as a fragment and would not be found in the natural state.

As used herein, the terms "polynucleotide" or "nucleic acid molecule" are intended to include DNA molecules (e.g., cDNA or genomic DNA) and RNA molecules (e.g., mRNA) and analogs of the DNA or RNA generated using nucleotide analogs. The nucleic acid molecule can be single-stranded or double-stranded, but preferably is double-stranded DNA. The nucleic acid may be synthesized using oligonucleotide analogs or derivatives (e.g., inosine or phosphorothioate nucleotides). Such oligonucleotides can be used, for example, to prepare nucleic acids that have altered base-pairing abilities or increased resistance to nucleases.

Another embodiment of the invention provides an isolated nucleic acid molecule which is antisense to a PEC38 nucleic acid molecule, e.g., the coding strand of a PEC38 nucleic acid molecule. Also included within the scope of the invention are the complement strands of the nucleic acid molecules described herein.

#### **Sequencing errors**

The sequence information as provided herein should not be so narrowly construed as to require inclusion of erroneously identified bases. The specific sequences disclosed herein can be readily used to isolate the complete gene from filamentous fungi, in particular *A. niger* which in turn can easily be subjected to further sequence analyses thereby identifying sequencing errors.

Unless otherwise indicated, all nucleotide sequences determined by sequencing a DNA molecule herein were determined using an automated DNA sequencer and all amino acid sequences of polypeptides encoded by DNA molecules determined herein were predicted by translation of a DNA sequence determined as above. Therefore, as is known in the art for any DNA sequence determined by this automated approach, any nucleotide sequence determined herein may contain some errors. Nucleotide sequences determined by automation are typically at least about 90% identical, more typically at least about 95% to at least about 99.9% identical to the actual nucleotide sequence of the sequenced DNA molecule. The actual sequence can be more precisely determined by other approaches including manual DNA sequencing methods well known in the art. As is also known in the art, a single insertion or deletion in a determined nucleotide sequence compared to the actual sequence will cause a frame shift in translation of the nucleotide sequence such that the predicted amino acid sequence encoded by a determined nucleotide sequence will be completely

different from the amino acid sequence actually encoded by the sequenced DNA molecule, beginning at the point of such an insertion or deletion.

The person skilled in the art is capable of identifying such erroneously identified bases and knows how to correct for such errors.

5

#### **Nucleic acid fragments, probes and primers**

A nucleic acid molecule according to the invention may comprise only a portion or a fragment of the nucleic acid sequence shown in SEQ ID NO:1 or SEQ ID NO:2, for example a fragment which can be used as a probe or primer or a fragment encoding a portion of a PEC38 protein. The nucleotide sequence determined from the cloning of the PEC38 gene and cDNA allows for the generation of probes and primers designed for use in identifying and/or cloning other PEC38 family members, as well as PEC38 homologues from other species. The probe/primer typically comprises substantially purified oligonucleotide which typically comprises a region of nucleotide sequence that hybridizes preferably under highly stringent conditions to at least about 12 or 15, preferably about 18 or 20, preferably about 22 or 25, more preferably about 30, 35, 40, 45, 50, 55, 60, 65, or 75 or more consecutive nucleotides of a nucleotide sequence shown in SEQ ID NO:1 or SEQ ID NO: 2 or of a functional equivalent thereof.

Probes based on the PEC38 nucleotide sequences can be used to detect transcripts or genomic PEC38 sequences encoding the same or homologous proteins for instance in other organisms. In preferred embodiments, the probe further comprises a label group attached thereto, e.g., the label group can be a radioisotope, a fluorescent compound, an enzyme, or an enzyme cofactor. Such probes can also be used as part of a diagnostic test kit for identifying cells which express a PEC38 protein.

#### **Identity & homology**

The terms "homology" or "percent identity" are used interchangeably herein. For the purpose of this invention, it is defined here that in order to determine the percent identity of two amino acid sequences or of two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in the sequence of a first amino acid or nucleic acid sequence for optimal alignment with a second amino or nucleic acid

sequence). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences (i.e., % identity = number of identical positions/total number of positions (i.e. overlapping positions) x 100). Preferably, the two sequences are the same length.

The skilled person will be aware of the fact that several different computer programmes are available to determine the homology between two sequences. For instance, a comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm. In a preferred embodiment, the percent identity between two amino acid sequences is determined using the Needleman and Wunsch (J. Mol. Biol. (48):444-453 (1970)) algorithm which has been incorporated into the GAP program in the GCG software package (available at <http://www.gcg.com>), using either a Blossom 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6. The skilled person will appreciate that all these different parameters will yield slightly different results but that the overall percentage identity of two sequences is not significantly altered when using different algorithms.

In yet another embodiment, the percent identity between two nucleotide sequences is determined using the GAP program in the GCG software package (available at <http://www.gcg.com>), using a NWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6. In another embodiment, the percent identity two amino acid or nucleotide sequence is determined using the algorithm of E. Meyers and W. Miller (CABIOS, 4:11-17 (1989) which has been incorporated into the ALIGN program (version 2.0) (available at: <http://vega.igh.cnrs.fr/bin/align-guess.cgi>) using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4.

The nucleic acid and protein sequences of the present invention can further be used as a "query sequence" to perform a search against public databases to, for example, identify other family members or related sequences. Such searches can be performed using the NBLAST and XBLAST programs (version 2.0) of Altschul, et al. (1990) J. Mol. Biol. 215:403—10. BLAST nucleotide searches can be performed with the NBLAST program, score = 100, wordlength =

12 to obtain nucleotide sequences homologous to PEC38 nucleic acid molecules of the invention. BLAST protein searches can be performed with the XBLAST program, score = 50, wordlength = 3 to obtain amino acid sequences homologous to PEC38 protein molecules of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al., (1997) Nucleic Acids Res. 25(17):3389-3402. When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used. See <http://www.ncbi.nlm.nih.gov>.

## 10 Hybridisation

As used herein, the term "hybridizing" is intended to describe conditions for hybridization and washing under which nucleotide sequences at least about 50%, at least about 60%, at least about 70%, more preferably at least about 80%, even more preferably at least about 85% to 90%, more preferably at least 95% homologous to each other typically remain hybridized to each other.

A preferred, non-limiting example of such hybridization conditions are hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45 °C, followed by one or more washes in 1 X SSC, 0.1 % SDS at 50 °C, preferably at 55 °C, preferably at 60 °C and even more preferably at 65 °C.

Highly stringent conditions include, for example, hybridizing at 68 °C in 5x SSC/5x Denhardt's solution / 1.0% SDS and washing in 0.2x SSC/0.1% SDS at room temperature. Alternatively, washing may be performed at 42 °C.

The skilled artisan will know which conditions to apply for stringent and highly stringent hybridisation conditions. Additional guidance regarding such conditions is readily available in the art, for example, in Sambrook et al., 1989, Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, N.Y.; and Ausubel et al. (eds.), 1995, Current Protocols in Molecular Biology, (John Wiley & Sons, N.Y.).

Of course, a polynucleotide which hybridizes only to a poly A sequence (such as the 3' terminal poly(A) tract of mRNAs), or to a complementary stretch of T (or U) residues, would not be included in a polynucleotide of the invention used to specifically hybridize to a portion of a nucleic acid of the invention, since such a polynucleotide would hybridize to any nucleic acid molecule containing a poly (A) stretch or the complement thereof (e.g., practically any double-standed cDNA clone).

**Obtaining full length DNA from other organisms**

5 In a typical approach, cDNA libraries constructed from other organisms, e.g. filamentous fungi, in particular from the species *Aspergillus* can be screened.

For example, *Aspergillus* strains can be screened for homologous PEC38 polynucleotides by Northern blot analysis. Upon detection of transcripts homologous to polynucleotides according to the invention, cDNA  
10 libraries can be constructed from RNA isolated from the appropriate strain, utilizing standard techniques well known to those of skill in the art. Alternatively, a total genomic DNA library can be screened using a probe hybridisable to a PEC38 polynucleotide according to the invention.

Homologous gene sequences can be isolated, for example, by  
15 performing PCR using two degenerate oligonucleotide primer pools designed on the basis of nucleotide sequences as taught herein.

The template for the reaction can be cDNA obtained by reverse transcription of mRNA prepared from strains known or suspected to express a polynucleotide according to the invention. The PCR product can be subcloned and  
20 sequenced to ensure that the amplified sequences represent the sequences of a new PEC38 nucleic acid sequence, or a functional equivalent thereof.

The PCR fragment can then be used to isolate a full length cDNA clone by a variety of known methods. For example, the amplified fragment can be labeled and used to screen a bacteriophage or cosmid cDNA library.  
25 Alternatively, the labeled fragment can be used to screen a genomic library.

PCR technology also can be used to isolate full length cDNA sequences from other organisms. For example, RNA can be isolated, following standard procedures, from an appropriate cellular or tissue source. A reverse transcription reaction can be performed on the RNA using an oligonucleotide  
30 primer specific for the most 5' end of the amplified fragment for the priming of first strand synthesis.

The resulting RNA/DNA hybrid can then be "tailed" (e.g., with guanines) using a standard terminal transferase reaction, the hybrid can be digested with RNase H, and second strand synthesis can then be primed (e.g.,  
35 with a poly-C primer). Thus, cDNA sequences upstream of the amplified fragment can easily be isolated. For a review of useful cloning strategies, see e.g., Sambrook et al., supra; and Ausubel et al., supra.

## Vectors

Another aspect of the invention pertains to vectors, preferably  
5 expression vectors, containing a nucleic acid encoding a PEC38 protein or a  
functional equivalent thereof. As used herein, the term "vector" refers to a nucleic  
acid molecule capable of transporting another nucleic acid to which it has been  
linked. One type of vector is a "plasmid", which refers to a circular double stranded  
10 DNA loop into which additional DNA segments can be ligated. Another type of  
vector is a viral vector, wherein additional DNA segments can be ligated into the  
viral genome. Certain vectors are capable of autonomous replication in a host cell  
into which they are introduced (e.g., bacterial vectors having a bacterial origin of  
replication and episomal mammalian vectors). Other vectors (e.g., non-episomal  
15 mammalian vectors) are integrated into the genome of a host cell upon  
introduction into the host cell, and thereby are replicated along with the host  
genome. Moreover, certain vectors are capable of directing the expression of  
genes to which they are operatively linked. Such vectors are referred to herein as  
"expression vectors". In general, expression vectors of utility in recombinant DNA  
20 techniques are often in the form of plasmids. The terms "plasmid" and "vector" can  
be used interchangeably herein as the plasmid is the most commonly used form  
of vector. However, the invention is intended to include such other forms of  
expression vectors, such as viral vectors (e.g., replication defective retroviruses,  
adenoviruses and adeno-associated viruses), which serve equivalent functions.

The recombinant expression vectors of the invention comprise a  
25 nucleic acid of the invention in a form suitable for expression of the nucleic acid in  
a host cell, which means that the recombinant expression vector includes one or  
more regulatory sequences, selected on the basis of the host cells to be used for  
expression, which is operatively linked to the nucleic acid sequence to be  
expressed. Within a recombinant expression vector, "operatively linked" is  
30 intended to mean that the nucleotide sequence of interest is linked to the  
regulatory sequence(s) in a manner which allows for expression of the nucleotide  
sequence (e.g., in an *in vitro* transcription/translation system or in a host cell when  
the vector is introduced into the host cell). The term "regulatory sequence" is  
intended to include promoters, enhancers and other expression control elements  
35 (e.g., polyadenylation signal). Such regulatory sequences are described, for  
example, in Goeddel; *Gene Expression Technology: Methods in Enzymology* 185,  
Academic Press, San Diego, CA (1990). Regulatory sequences include those



which direct constitutive expression of a nucleotide sequence in many types of host cells and those which direct expression of the nucleotide sequence only in a certain host cell (e.g. tissue-specific regulatory sequences). It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, etc. The expression vectors of the invention can be introduced into host cells to thereby produce proteins or peptides, encoded by nucleic acids as described herein (e.g. PEC38 proteins, mutant forms of PEC38 proteins, fragments, variants or functional equivalents thereof, fusion proteins, etc.).

The recombinant expression vectors of the invention can be designed for expression of PEC38 proteins in prokaryotic or eukaryotic cells. For example, PEC38 proteins can be expressed in bacterial cells such as *E. coli*, insect cells (using baculovirus expression vectors) yeast cells or mammalian cells. Suitable host cells are discussed further in Goeddel, *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, CA (1990). Alternatively, the recombinant expression vector can be transcribed and translated *in vitro*, for example using T7 promoter regulatory sequences and T7 polymerase.

Expression vectors useful in the present invention include chromosomal-, episomal- and virus-derived vectors e.g., vectors derived from bacterial plasmids, bacteriophage, yeast episome, yeast chromosomal elements, viruses such as baculoviruses, papova viruses, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses, and vectors derived from combinations thereof, such as those derived from plasmid and bacteriophage genetic elements, such as cosmids and phagemids.

The DNA insert should be operatively linked to an appropriate promoter, such as the phage lambda PL promoter, the *E. coli* lac, trp and tac promoters, the SV40 early and late promoters and promoters of retroviral LTRs, to name a few. Other suitable promoters will be known to the skilled person. In a specific embodiment, promoters are preferred that are capable of directing a high expression level of pectinases in filamentous fungi. Such promoters are known in the art. The expression constructs may contain sites for transcription initiation, termination, and, in the transcribed region, a ribosome binding site for translation. The coding portion of the mature transcripts expressed by the constructs will include a translation initiating AUG at the beginning and a termination codon

appropriately positioned at the end of the polypeptide to be translated.

Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques. As used herein, the terms "transformation" and "transfection" are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid (e.g., DNA) into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, transduction, infection, lipofection, cationic lipid-mediated transfection or electroporation. Suitable methods for transforming or transfecting host cells can be found in Sambrook, et al. (*Molecular Cloning: A Laboratory Manual*, 2<sup>nd</sup>, ed. Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989), Davis et al., *Basic Methods in Molecular Biology* (1986) and other laboratory manuals.

For stable transfection of mammalian cells, it is known that, depending upon the expression vector and transfection technique used, only a small fraction of cells may integrate the foreign DNA into their genome. In order to identify and select these integrants, a gene that encodes a selectable marker (e.g., resistance to antibiotics) is generally introduced into the host cells along with the gene of interest. Preferred selectable markers include those which confer resistance to drugs, such as G418, hygromycin and methotrexate. Nucleic acid encoding a selectable marker can be introduced into a host cell on the same vector as that encoding a PEC38 protein or can be introduced on a separate vector. Cells stably transfected with the introduced nucleic acid can be identified by drug selection (e.g. cells that have incorporated the selectable marker gene will survive, while the other cells die).

Expression of proteins in prokaryotes is often carried out in *E. coli* with vectors containing constitutive or inducible promoters directing the expression of either fusion or non-fusion proteins. Fusion vectors add a number of amino acids to a protein encoded therein, e.g. to the amino terminus of the recombinant protein. Such fusion vectors typically serve three purposes: 1) to increase expression of recombinant protein; 2) to increase the solubility of the recombinant protein; and 3) to aid in the purification of the recombinant protein by acting as a ligand in affinity purification. Often, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant protein to enable separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein. Such enzymes, and their cognate recognition sequences, include Factor Xa, thrombin and

enterokinase.

As indicated, the expression vectors will preferably contain selectable markers. Such markers include dihydrofolate reductase or neomycin resistance for eukarotic cell culture and tetracycline or ampicillin resistance for culturing in *E. coli* and other bacteria. Representative examples of appropriate host include bacterial cells, such as *E. coli*, *Streptomyces* and *Salmonella typhimurium*; fungal cells, such as yeast; insect cells such as *Drosophila* S2 and *Spodoptera* Sf9; animal cells such as CHO, COS and Bowes melanoma; and plant cells. Appropriate culture mediums and conditions for the above-described host cells are known in the art.

Among vectors preferred for use in bacteria are pQE70, pQE60 and pQE-9, available from Qiagen; pBS vectors, Phagescript vectors, Bluescript vectors, pNH8A, pNH16A, pNH18A, pNH46A, available from Stratagene; and ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 available from Pharmacia. Among preferred eukaryotic vectors are PWLNEO, pSV2CAT, pOG44, pZT1 and pSG available from Stratagene; and pSVK3, pBPV, pMSG and pSVL available from Pharmacia. Other suitable vectors will be readily apparent to the skilled artisan.

Among known bacterial promoters for use in the present invention include *E. coli* *lacI* and *lacZ* promoters, the T3 and T7 promoters, the *gpt* promoter, the lambda PR, PL promoters and the *trp* promoter, the HSV thymidine kinase promoter, the early and late SV40 promoters, the promoters of retroviral LTRs, such as those of the Rous sarcoma virus ("RSV"), and metallothionein promoters, such as the mouse metallothionein-I promoter.

Transcription of the DNA encoding the polypeptides of the present invention by higher eukaryotes may be increased by inserting an enhancer sequence into the vector. Enhancers are cis-acting elements of DNA, usually about from 10 to 300 bp that act to increase transcriptional activity of a promoter in a given host cell-type. Examples of enhancers include the SV40 enhancer, which is located on the late side of the replication origin at bp 100 to 270, the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers.

For secretion of the translated protein into the lumen of the endoplasmic reticulum, into the periplasmic space or into the extracellular environment, appropriate secretion signal may be incorporated into the expressed polypeptide. The signals may be endogenous to the polypeptide or they may be heterologous signals.

The polypeptide may be expressed in a modified form, such as a fusion protein, and may include not only secretion signals but also additional heterologous functional regions. Thus, for instance, a region of additional amino acids, particularly charged amino acids, may be added to the N-terminus of the polypeptide to improve stability and persistence in the host cell, during purification or during subsequent handling and storage. Also, peptide moieties may be added to the polypeptide to facilitate purification.

#### **Polypeptides according to the invention**

The invention provides an isolated polypeptide having the amino acid sequence according to SEQ ID NO: 3, an amino acid sequence obtainable by expressing the polynucleotide of SEQ ID NO: 1 in an appropriate host, as well as an amino acid sequence obtainable by expressing the polynucleotide sequences of SEQ ID NO: 2 in an appropriate host. Also, a peptide or polypeptide comprising a functional equivalent of the above polypeptides is comprised within the present invention. The above polypeptides are collectively comprised in the term "polypeptides according to the invention"

The terms "peptide" and "oligopeptide" are considered synonymous (as is commonly recognized) and each term can be used interchangeably as the context requires to indicate a chain of at least two amino acids coupled by peptidyl linkages. The word "polypeptide" is used herein for chains containing more than seven amino acid residues. All oligopeptide and polypeptide formulas or sequences herein are written from left to right and in the direction from amino terminus to carboxy terminus. The one-letter code of amino acids used herein is commonly known in the art and can be found in Sambrook, et al. (*Molecular Cloning: A Laboratory Manual, 2<sup>nd</sup>, ed. Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989*)

By "isolated" polypeptide or protein is intended a polypeptide or protein removed from its native environment. For example, recombinantly produced polypeptides and proteins expressed in host cells are considered isolated for the purpose of the invention as are native or recombinant polypeptides which have been substantially purified by any suitable technique such as, for example, the single-step purification method disclosed in Smith and Johnson, Gene 67:31-40 (1988).

The PEC38 pectinase according to the invention can be recovered and purified from recombinant cell cultures by well-known methods

including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography ("HPLC") is employed for purification.

Polypeptides of the present invention include naturally purified products, products of chemical synthetic procedures, and products produced by recombinant techniques from a prokaryotic or eukaryotic host, including, for example, bacterial, yeast, higher plant, insect and mammalian cells. Depending upon the host employed in a recombinant production procedure, the polypeptides of the present invention may be glycosylated or may be non-glycosylated. In addition, polypeptides of the invention may also include an initial modified methionine residue, in some cases as a result of host-mediated processes.

#### **Protein fragments**

The invention also features biologically active fragments of the polypeptides according to the invention.

Biologically active fragments of a polypeptide of the invention include polypeptides comprising amino acid sequences sufficiently identical to or derived from the amino acid sequence of the PEC38 protein (e.g., the amino acid sequence of SEQ ID NO: 3), which include fewer amino acids than the full length protein, and exhibit at least one biological activity of the corresponding full-length protein. Typically, biologically active fragments comprise a domain or motif with at least one activity of the PEC38 protein. A biologically active fragment of a protein of the invention can be a polypeptide which is, for example, 10, 25, 50, 100 or more amino acids in length. Moreover, other biologically active portions, in which other regions of the protein are deleted, can be prepared by recombinant techniques and evaluated for one or more of the biological activities of the native form of a polypeptide of the invention.

The invention also features nucleic acid fragments which encode the above biologically active fragments of the PEC38 protein.

#### **Fusion proteins**

The proteins of the present invention or functional equivalents thereof, e.g., biologically active portions thereof, can be operatively linked to a

non-PEC38 polypeptide (e.g., heterologous amino acid sequences) to form fusion proteins. As used herein, a PEC38 "chimeric protein" or "fusion protein" comprises a PEC38 polypeptide operatively linked to a non-PEC38 polypeptide. A "PEC38 polypeptide" refers to a polypeptide having an amino acid sequence  
5 corresponding to PEC38, whereas a "non-PEC38 polypeptide" refers to a polypeptide having an amino acid sequence corresponding to a protein which is not substantially homologous to the PEC38 protein, e.g., a protein which is different from the PEC38 protein and which is derived from the same or a different organism. Within a PEC38 fusion protein the PEC38 polypeptide can correspond  
10 to all or a portion of a PEC38 protein. In a preferred embodiment, a PEC38 fusion protein comprises at least one biologically active fragment of a PEC38 protein. In another preferred embodiment, a PEC38 fusion protein comprises at least two biologically active portions of a PEC38 protein. Within the fusion protein, the term "operatively linked" is intended to indicate that the PEC38 polypeptide and the  
15 non-PEC38 polypeptide are fused in-frame to each other. The non-PEC38 polypeptide can be fused to the N-terminus or C-terminus of the PEC38 polypeptide.

For example, in one embodiment, the fusion protein is a GST-PEC38 fusion protein in which the PEC38 sequences are fused to the C-terminus  
20 of the GST sequences. Such fusion proteins can facilitate the purification of recombinant PEC38. In another embodiment, the fusion protein is a PEC38 protein containing a heterologous signal sequence at its N-terminus. In certain host cells (e.g., mammalian and Yeast host cells), expression and/or secretion of PEC38 can be increased through use of a heterologous signal sequence.

25 In another example, the gp67 secretory sequence of the baculovirus envelope protein can be used as a heterologous signal sequence (*Current Protocols in Molecular Biology*, Ausubel et al., eds., John Wiley & Sons, 1992). Other examples of eukaryotic heterologous signal sequences include the secretory sequences of melittin and human placental alkaline phosphatase  
30 (Stratagene; La Jolla, California). In yet another example, useful prokaryotic heterologous signal sequences include the phoA secretory signal (Sambrook et al., *supra*) and the protein A secretory signal (Pharmacia Biotech; Piscataway, New Jersey).

A signal sequence can be used to facilitate secretion and  
35 isolation of a protein or polypeptide of the invention. Signal sequences are typically characterized by a core of hydrophobic amino acids which are generally

cleaved from the mature protein during secretion in one or more cleavage events. Such signal peptides contain processing sites that allow cleavage of the signal sequence from the mature proteins as they pass through the secretory pathway. The signal sequence directs secretion of the protein, such as from a eukaryotic host into which the expression vector is transformed, and the signal sequence is subsequently or concurrently cleaved. The protein can then be readily purified from the extracellular medium by art recognized methods. Alternatively, the signal sequence can be linked to the protein of interest using a sequence which facilitates purification, such as with a GST domain. Thus, for instance, the sequence encoding the polypeptide may be fused to a marker sequence, such as a sequence encoding a peptide, which facilitates purification of the fused polypeptide. In certain preferred embodiments of this aspect of the invention, the marker sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (Qiagen, Inc.), among others, many of which are commercially available. As described in *Gentz et al, Proc. Natl. Acad. Sci. USA 86:821-824 (1989)*, for instance, hexa-histidine provides for convenient purification of the fusion protein. The HA tag is another peptide useful for purification which corresponds to an epitope derived of influenza hemagglutinin protein, which has been described by Wilson *et al.*, *Cell 37:767 (1984)*, for instance.

Preferably, a PEC38 chimeric or fusion protein of the invention is produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different polypeptide sequences are ligated together in-frame in accordance with conventional techniques, for example by employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be annealed and reamplified to generate a chimeric gene sequence (see, for example, *Current Protocols in Molecular Biology*, eds. Ausubel *et al.* John Wiley & Sons: 1992). Moreover, many expression vectors are commercially available that already encode a fusion moiety (e.g, a GST polypeptide). A PEC38-encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the PEC38

protein.

### **Functional equivalents**

5                   The terms "functional equivalents" and "functional variants" are used interchangeably herein. Functional equivalents of PEC38 DNA are isolated DNA fragments that encode a polypeptide that exhibits a particular function of the PEC38 *A. niger* pectinase as defined herein. A functional equivalent of a PEC38 polypeptide according to the invention is a polypeptide that exhibits at least one  
10                   function of an *A. niger* pectinase as defined herein. Functional equivalents therefore also encompass biologically active fragments.

                  Functional protein or polypeptide equivalents may contain only conservative substitutions of one or more amino acids of SEQ ID NO: 3 or substitutions, insertions or deletions of non-essential amino acids. Accordingly, a  
15                   non-essential amino acid is a residue that can be altered in SEQ ID NO: 3 without substantially altering the biological function. For example, amino acid residues that are conserved among the PEC38 proteins of the present invention, are predicted to be particularly unamenable to alteration. Furthermore, amino acids conserved among the PEC38 proteins according to the present invention and  
20                   other pectinases are not likely to be amenable to alteration.

                  The term "conservative substitution" is intended to mean that a substitution in which the amino acid residue is replaced with an amino acid residue having a similar side chain. These families are known in the art and include amino acids with basic side chains (e.g. lysine, arginine and histidine),  
25                   acidic side chains (e.g. aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagines, glutamine, serine, threonine, tyrosine, cysteine), non-polar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine tryptophan,  
30                   histidine).

                  Functional nucleic acid equivalents may typically contain silent mutations or mutations that do not alter the biological function of encoded polypeptide. Accordingly, the invention provides nucleic acid molecules encoding PEC38 proteins that contain changes in amino acid residues that are not essential  
35                   for a particular biological activity. Such PEC38 proteins differ in amino acid sequence from SEQ ID NO: 3 yet retain at least one biological activity. In one embodiment the isolated nucleic acid molecule comprises a nucleotide sequence



encoding a protein, wherein the protein comprises a substantially homologous amino acid sequence of at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more homologous to the amino acid sequence shown in SEQ ID NO: 3.

5                   For example, guidance concerning how to make phenotypically silent amino acid substitutions is provided in Bowie, J.U. et al., Science 247:1306-1310 (1990) wherein the authors indicate that there are two main approaches for studying the tolerance of an amino acid sequence to change. The first method relies on the process of evolution, in which mutations are either accepted or  
10 rejected by natural selection. The second approach uses genetic engineering to introduce amino acid changes at specific positions of a cloned gene and selects or screens to identify sequences that maintain functionality. As the authors state, these studies have revealed that proteins are surprisingly tolerant of amino acid substitutions. The authors further indicate which changes are likely to be  
15 permissive at a certain position of the protein. For example, most buried amino acid residues require non-polar side chains, whereas few features of surface side chains are generally conserved. Other such phenotypically silent substitutions are described in Bowie et al, supra, and the references cited therein.

                  An isolated nucleic acid molecule encoding a PEC38 protein  
20 homologous to the protein according to SEQ ID NO: 3 can be created by introducing one or more nucleotide substitutions, additions or deletions into the coding nucleotide sequences according to SEQ ID NO: 1 or SEQ ID NO: 2 such that one or more amino acid substitutions, deletions or insertions are introduced into the encoded protein. Such mutations may be introduced by standard  
25 techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis.

                  The term "functional equivalents" also encompasses orthologues of the *A. niger* PEC38 protein. Orthologues of the *A. niger* PEC38 protein are proteins that can be isolated from other strains or species and possess a similar or identical biological activity. Such orthologues can readily be identified  
30 as comprising an amino acid sequence that is substantially homologous to SEQ ID NO: 3.

                  As defined herein, the term "substantially homologous" refers to a first amino acid or nucleotide sequence which contains a sufficient or minimum number of identical or equivalent (e.g., with similar side chain) amino acids or  
35 nucleotides to a second amino acid or nucleotide sequence such that the first and the second amino acid or nucleotide sequences have a common domain. For

example, amino acid or nucleotide sequences which contain a common domain having about 60%, preferably 65%, more preferably 70%, even more preferably 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity or more are defined herein as sufficiently identical.

5                   Also, nucleic acids encoding other PEC38 family members, which thus have a nucleotide sequence that differs from SEQ ID NO: 1 or SEQ ID NO: 2, are within the scope of the invention. Moreover, nucleic acids encoding PEC38 proteins from different species which thus have a nucleotide sequence which differs from SEQ ID NO: 1 or SEQ ID NO: 2 are within the scope of the  
10                  invention.

                  Nucleic acid molecules corresponding to variants (e.g. natural allelic variants) and homologues of the PEC38 DNA of the invention can be isolated based on their homology to the PEC38 nucleic acids disclosed herein using the cDNAs disclosed herein or a suitable fragment thereof, as a  
15                  hybridisation probe according to standard hybridisation techniques preferably under highly stringent hybridisation conditions.

                  In addition to naturally occurring allelic variants of the PEC38 sequence, the skilled person will recognise that changes can be introduced by mutation into the nucleotide sequences of SEQ ID NO: 1 or SEQ ID NO: 2 thereby  
20                  leading to changes in the amino acid sequence of the PEC38 protein without substantially altering the function of the PEC38 protein.

                  In another aspect of the invention, improved PEC38 proteins are provided. Improved PEC38 proteins are proteins wherein at least one biological activity is improved. Such proteins may be obtained by randomly introducing  
25                  mutations along all or part of the PEC38 coding sequence, such as by saturation mutagenesis, and the resulting mutants can be expressed recombinantly and screened for biological activity. For instance, the art provides for standard assays for measuring the enzymatic activity of pectinases and thus improved proteins may easily be selected.

30                  In a preferred embodiment the PEC38 protein has an amino acid sequence according to SEQ ID NO: 3. In another embodiment, the PEC38 polypeptide is substantially homologous to the amino acid sequence according to SEQ ID NO: 3 and retains at least one biological activity of a polypeptide according to SEQ ID NO: 3, yet differs in amino acid sequence due to natural  
35                  variation or mutagenesis as described above.

                  In a further preferred embodiment, the PEC38 protein has an

amino acid sequence encoded by an isolated nucleic acid fragment capable of hybridising to a nucleic acid according to SEQ ID NO: 1 or SEQ ID NO: 2, preferably under highly stringent hybridisation conditions.

Accordingly, the PEC38 protein is a protein which comprises an amino acid sequence at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more homologous to the amino acid sequence shown in SEQ ID NO: 3 and retains at least one functional activity of the polypeptide according to SEQ ID NO: 3.

Functional equivalents of a protein according to the invention can also be identified e.g. by screening combinatorial libraries of mutants, e.g. truncation mutants, of the protein of the invention for pectinase activity. In one embodiment, a variegated library of variants is generated by combinatorial mutagenesis at the nucleic acid level. A variegated library of variants can be produced by, for example, enzymatically ligating a mixture of synthetic oligonucleotides into gene sequences such that a degenerate set of potential protein sequences is expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins (e.g., for phage display). There are a variety of methods that can be used to produce libraries of potential variants of the polypeptides of the invention from a degenerate oligonucleotide sequence. Methods for synthesizing degenerate oligonucleotides are known in the art (see, e.g., Narang (1983) Tetrahedron 39:3; Itakura et al. (1984) Annu. Rev. Biochem. 53:323; Itakura et al. (1984) Science 198:1056; Ike et al. (1983) Nucleic Acid Res. 11:477).

In addition, libraries of fragments of the coding sequence of a polypeptide of the invention can be used to generate a variegated population of polypeptides for screening a subsequent selection of variants. For example, a library of coding sequence fragments can be generated by treating a double stranded PCR fragment of the coding sequence of interest with a nuclease under conditions wherein nicking occurs only about once per molecule, denaturing the double stranded DNA, renaturing the DNA to form double stranded DNA which can include sense/antisense pairs from different nicked products, removing single stranded portions from reformed duplexes by treatment with S1 nuclease, and ligating the resulting fragment library into an expression vector. By this method, an expression library can be derived which encodes N-terminal and internal fragments of various sizes of the protein of interest.

Several techniques are known in the art for screening gene

products of combinatorial libraries made by point mutations of truncation, and for screening cDNA libraries for gene products having a selected property. The most widely used techniques, which are amenable to high through-put analysis, for screening large gene libraries typically include cloning the gene library into  
5 replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the combinatorial genes under conditions in which detection of a desired activity facilitates isolation of the vector encoding the gene whose product was detected. Recursive ensemble mutagenesis (REM), a technique which enhances the frequency of functional mutants in the libraries, can  
10 be used in combination with the screening assays to identify variants of a protein of the invention (Arkin and Yourvan (1992) Proc. Natl. Acad. Sci. USA 89:7811-7815; Delgrave et al. (1993) Protein Engineering 6(3):327-331).

In addition to the PEC38 gene sequence shown in SEQ ID NO: 1, it will be apparent for the person skilled in the art that DNA sequence  
15 polymorphisms that may lead to changes in the amino acid sequence of the PEC38 protein may exist within a given population. Such genetic polymorphisms may exist in cells from different populations or within a population due to natural allelic variation. Allelic variants may also include functional equivalents.

Fragments of a polynucleotide according to the invention may  
20 also comprise polynucleotides not encoding functional polypeptides. Such polynucleotides may function as probes or primers for a PCR reaction.

Nucleic acids according to the invention irrespective of whether they encode functional or non-functional polypeptides, can be used as hybridization probes or polymerase chain reaction (PCR) primers. Uses of the  
25 nucleic acid molecules of the present invention that do not encode a polypeptide having a PEC38 activity include, inter alia, (1) isolating the gene encoding the PEC38 protein, or allelic variants thereof from a cDNA library e.g. from other organisms than *A. niger*; (2) in situ hybridization (e.g. FISH) to metaphase chromosomal spreads to provide precise chromosomal location of the PEC38  
30 gene as described in Verma et al., Human Chromosomes: a Manual of Basic Techniques, Pergamon Press, New York (1988); (3) Northern blot analysis for detecting expression of PEC38 mRNA in specific tissues and/or cells and 4) probes and primers that can be used as a diagnostic tool to analyse the presence of a nucleic acid hybridisable to the PEC38 probe in a given biological (e.g. tissue)  
35 sample.

Also encompassed by the invention is a method of obtaining a

functional equivalent of a PEC38 gene or cDNA. Such a method entails obtaining a labelled probe that includes an isolated nucleic acid which encodes all or a portion of the sequence according to SEQ ID NO: 3 or a variant thereof; screening a nucleic acid fragment library with the labelled probe under conditions that allow  
5 hybridisation of the probe to nucleic acid fragments in the library, thereby forming nucleic acid duplexes, and preparing a full-length gene sequence from the nucleic acid fragments in any labelled duplex to obtain a gene related to the PEC38 gene.

In one embodiment, a PEC38 nucleic acid of the invention is at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%,  
10 97%, 98%, 99%, or more homologous to a nucleic acid sequence shown in SEQ ID NO: 1, SEQ ID NO: 2 or the complement thereof.

In another preferred embodiment a PEC38 polypeptide of the invention is at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more homologous to the amino acid  
15 sequence shown in SEQ ID NO: 3.

### **Host cells**

In another embodiment, the invention features cells, e.g.,  
20 transformed host cells or recombinant host cells that contain a nucleic acid encompassed by the invention. A "transformed cell" or "recombinant cell" is a cell into which (or into an ancestor of which) has been introduced, by means of recombinant DNA techniques, a nucleic acid according to the invention. Both prokaryotic and eukaryotic cells are included, e.g., bacteria, fungi, yeast, and the  
25 like, especially preferred are cells from filamentous fungi, in particular *Aspergillus niger*.

A host cell can be chosen that modulates the expression of the inserted sequences, or modifies and processes the gene product in a specific, desired fashion. Such modifications (e.g., glycosylation) and processing (e.g.,  
30 cleavage) of protein products may facilitate optimal functioning of the protein.

Various host cells have characteristic and specific mechanisms for post-translational processing and modification of proteins and gene products. Appropriate cell lines or host systems familiar to those of skill in the art of molecular biology and/or microbiology can be chosen to ensure the desired and  
35 correct modification and processing of the foreign protein expressed. To this end, eukaryotic host cells that possess the cellular machinery for proper processing of the primary transcript, glycosylation, and phosphorylation of the gene product can

be used. Such host cells are well known in the art.

Host cells also include, but are not limited to, mammalian cell lines such as CHO, VERO, BHK, HeLa, COS, MDCK, 293, 3T3, WI38, and choroid plexus cell lines.

5 If desired, the polypeptides according to the invention can be produced by a stably-transfected cell line. A number of vectors suitable for stable transfection of mammalian cells are available to the public, methods for constructing such cell lines are also publicly known, e.g., in Ausubel et al. (*supra*).

## 10 Antibodies

The invention further features antibodies, such as monoclonal or polyclonal antibodies, that specifically bind PEC38 proteins according to the invention.

15 As used herein, the term "antibody" (Ab) or "monoclonal antibody" (Mab) is meant to include intact molecules as well as antibody fragments (such as, for example, Fab and F(ab')<sub>2</sub> fragments) which are capable of specifically binding to PEC38 protein. Fab and F(ab')<sub>2</sub> fragments lack the Fc fragment of intact antibody, clear more rapidly from the circulation, and may have  
20 less non-specific tissue binding of an intact antibody (Wahl *et al.*, *J. Nucl. Med.* 24:316-325 (1983)). Thus, these fragments are preferred.

The antibodies of the present invention may be prepared by any of a variety of methods. For example, cells expressing the PEC38 protein or an antigenic fragment thereof can be administered to an animal in order to induce the  
25 production of sera containing polyclonal antibodies. In a preferred method, a preparation of PEC38 protein is prepared and purified to render it substantially free of natural contaminants. Such a preparation is then introduced into an animal in order to produce polyclonal antisera of greater specific activity.

In the most preferred method, the antibodies of the present  
30 invention are monoclonal antibodies (or PEC38 protein binding fragments thereof). Such monoclonal antibodies can be prepared using hybridoma technology (Kohler *et al.*, *Nature* 256:495 (1975); Kohler *et al.*, *Eur. J. Immunol.* 6:511 (1976); Hammerling *et al.*, In: *Monoclonal Antibodies and T-Cell Hybridomas*, Elsevier, N.Y., pp. 563-681 (1981)). In general, such procedures  
35 involve immunizing an animal (preferably a mouse) with a PEC38 protein antigen or, with a PEC38 protein expressing cell. The splenocytes of such mice are extracted and fused with a suitable myeloma cell line. Any suitable myeloma cell

line may be employed in accordance with the present invention; however, it is preferably to employ the parent myeloma cell line (SP<sub>2</sub>O), available from the American Type Culture Collection, Rockville, Maryland. After fusion, the resulting hybridoma cells are selectively maintained in HAT medium, and then cloned by limiting dilution as described by Wands *et al.* (*Gastro-enterology* 80:225-232 (1981)). The hybridoma cells obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding the PEC38 protein antigen. In general, the polypeptides can be coupled to a carrier protein, such as KLH, as described in Ausubel *et al.*, supra, mixed with an adjuvant, and injected into a host mammal.

In particular, various host animals can be immunized by injection of a polypeptide of interest. Examples of suitable host animals include rabbits, mice, guinea pigs, and rats. Various adjuvants can be used to increase the immunological response, depending on the host species, including but not limited to Freund's (complete and incomplete), adjuvant mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, dinitrophenol, BCG (bacille Calmette-Guerin) and *Corynebacterium parvum*. Polyclonal antibodies are heterogeneous populations of antibody molecules derived from the sera of the immunized animals.

Such antibodies can be of any immunoglobulin class including IgG, IgM, IgE, IgA, IgD, and any subclass thereof. The hybridomas producing the mAbs of this invention can be cultivated *in vitro* or *in vivo*.

Once produced, polyclonal or monoclonal antibodies are tested for specific recognition of a PEC38 polypeptide or functional equivalent thereof in an immunoassay, such as a Western blot or immunoprecipitation analysis using standard techniques, e.g., as described in Ausubel *et al.*, supra. Antibodies that specifically bind to PEC38 proteins or functional equivalents thereof are useful in the invention. For example, such antibodies can be used in an immunoassay to detect PEC38 in pathogenic or non-pathogenic strains of *Aspergillus* (e.g., in *Aspergillus* extracts).

Preferably, antibodies of the invention are produced using fragments of the PEC38 polypeptides that appear likely to be antigenic, by criteria such as high frequency of charged residues. For example, such fragments may be generated by standard techniques of PCR, and then cloned into the pGEX expression vector (Ausubel *et al.*, supra). Fusion proteins may then be expressed

in *E. coli* and purified using a glutathione agarose affinity matrix as described in Ausubel, et al., supra. If desired, several (e.g., two or three) fusions can be generated for each protein, and each fusion can be injected into at least two rabbits. Antisera can be raised by injections in a series, typically including at least  
5 three booster injections. Typically, the antisera are checked for their ability to immunoprecipitate a recombinant PEC38 polypeptide or functional equivalents thereof whereas unrelated proteins may serve as a control for the specificity of the immune reaction.

Alternatively, techniques described for the production of single  
10 chain antibodies (U.S. Patent 4,946,778 and 4,704,692) can be adapted to produce single chain antibodies against a PEC38 polypeptide or functional equivalents thereof. Kits for generating and screening phage display libraries are commercially available e.g. from Pharmacia.

Additionally, examples of methods and reagents particularly  
15 amenable for use in generating and screening antibody display library can be found in, for example, U.S. Patent No. 5,223, 409; PCT Publication No. WO 92/18619; PCT Publication No. WO 91/17271; PCT Publication No. WO 20791; PCT Publication No. WO 92/20791; PCT Publication No. WO 92/15679; PCT Publication No. WO 93/01288; PCT Publication No. WO  
20 92/01047; PCT Publication No. WO 92/09690; PCT Publication No. WO 90/02809; Fuchs et al. (1991) *Bio/Technology* 9:1370-1372; Hay et al. (1992) *Hum. Antibod. Hybridomas* 3:81-85; Huse et al. (1989) *Science* 246:1275-1281; Griffiths et al. (1993) *EMBO J.* 12:725-734.

Polyclonal and monoclonal antibodies that specifically bind  
25 PEC38 polypeptides or functional equivalents thereof can be used, for example, to detect expression of a PEC38 gene or a functional equivalent thereof e.g. in another strain of *Aspergillus*. For example, PEC38 polypeptide can be readily detected in conventional immunoassays of *Aspergillus* cells or extracts. Examples of suitable assays include, without limitation, Western blotting, ELISAs,  
30 radioimmune assays, and the like.

By "specifically binds" is meant that an antibody recognizes and binds a particular antigen, e.g., a PEC38 polypeptide, but does not substantially recognize and bind other unrelated molecules in a sample.

Antibodies can be purified, for example, by affinity  
35 chromatography methods in which the polypeptide antigen is immobilized on a resin.



An antibody directed against a polypeptide of the invention (e.g., monoclonal antibody) can be used to isolate the polypeptide by standard techniques, such as affinity chromatography or immunoprecipitation. Moreover, such an antibody can be used to detect the protein (e.g., in a cellular lysate or cell supernatant) in order to evaluate the abundance and pattern of expression of the polypeptide. The antibodies can also be used diagnostically to monitor protein levels in cells or tissue as part of a clinical testing procedure, e.g., to, for example, determine the efficacy of a given treatment regimen or in the diagnosis of Aspergillosis..

Detection can be facilitated by coupling the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase,  $\beta$ -galactosidase, or acetylcholinesterase; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive materials include  $^{125}\text{I}$ ,  $^{131}\text{I}$ ,  $^{35}\text{S}$  or  $^3\text{H}$ .

Preferred epitopes encompassed by the antigenic peptide are regions that are located on the surface of the protein, e.g., hydrophilic regions. Hydrophobicity plots of the proteins of the invention can be used to identify hydrophilic regions.

The antigenic peptide of a protein of the invention comprises at least 7 (preferably 10, 15, 20, or 30) contiguous amino acid residues of the amino acid sequence of SEQ ID NO: 3 and encompasses an epitope of the protein such that an antibody raised against the peptide forms a specific immune complex with the protein.

Preferred epitopes encompassed by the antigenic peptide are regions of PEC38 that are located on the surface of the protein, e.g., hydrophilic regions, hydrophobic regions, alpha regions, beta regions, coil regions, turn regions and flexible regions.

### **Immunoassays**

Qualitative or quantitative determination of a polypeptide

according to the present invention in a biological sample can occur using any art-known method. Antibody-based techniques provide special advantages for assaying specific polypeptide levels in a biological sample.

5 In these, the specific recognition is provided by the primary antibody (polyclonal or monoclonal) but the secondary detection system can utilize fluorescent, enzyme, or other conjugated secondary antibodies. As a result, an immunocomplex is obtained.

Accordingly, the invention provides a method for diagnosing whether a certain organism is infected with *Aspergillus* comprising the steps of:

- 10
- Isolating a biological sample from said organism suspected to be infected with *Aspergillus*,
  - reacting said biological sample with an antibody according to the invention,
  - determining whether immune complexes are formed.

15 Tissues can also be extracted, e.g., with urea and neutral detergent, for the liberation of protein for Western-blot or dot/slot assay. This technique can also be applied to body fluids.

Other antibody-based methods useful for detecting PEC38 gene expression include immunoassays, such as the enzyme linked immunosorbent assay (ELISA) and the radioimmunoassay (RIA). For example, PEC38-specific  
20 monoclonal antibodies can be used both as an immunoabsorbent and as an enzyme-labeled probe to detect and quantify the PEC38 protein. The amount of PEC38 protein present in the sample can be calculated by reference to the amount present in a standard preparation using a linear regression computer algorithm. In another ELISA assay, two distinct specific monoclonal antibodies can  
25 be used to detect PEC38 protein in a biological fluid. In this assay, one of the antibodies is used as the immuno-absorbent and the other as the enzyme-labeled probe.

The above techniques may be conducted essentially as a "one-step" or "two-step" assay. The "one-step" assay involves contacting PEC38  
30 protein with immobilized antibody and, without washing, contacting the mixture with the labeled antibody. The "two-step" assay involves washing before contacting the mixture with the labeled antibody. Other conventional methods may also be employed as suitable. It is usually desirable to immobilize one component of the assay system on a support, thereby allowing other components of the  
35 system to be brought into contact with the component and readily removed from the sample.

Suitable enzyme labels include, for example, those from the oxidase group, which catalyze the production of hydrogen peroxide by reacting with substrate. Activity of an oxidase label may be assayed by measuring the concentration of hydrogen peroxide formed by the enzyme-labelled antibody/substrate reaction.

Besides enzymes, other suitable labels include radioisotopes, such as iodine ( $^{125}\text{I}$ ,  $^{127}\text{I}$ ), carbon ( $^{14}\text{C}$ ), sulphur ( $^{35}\text{S}$ ), tritium ( $^3\text{H}$ ), indium ( $^{112}\text{In}$ ), and technetium ( $^{99\text{m}}\text{Tc}$ ), and fluorescent labels, such as fluorescein and rhodamine, and biotin.

Specific binding of a test compound to a PEC38 polypeptide can be detected, for example, in vitro by reversibly or irreversibly immobilizing the PEC38 polypeptide on a substrate, e.g., the surface of a well of a 96-well polystyrene microtitre plate. Methods for immobilizing polypeptides and other small molecules are well known in the art. For example, the microtitre plates can be coated with a PEC38 polypeptide by adding the polypeptide in a solution (typically, at a concentration of 0.05 to 1 mg/ml in a volume of 1-100  $\mu\text{l}$ ) to each well, and incubating the plates at room temperature to 37  $^{\circ}\text{C}$  for 0.1 to 36 hours. Polypeptides that are not bound to the plate can be removed by shaking the excess solution from the plate, and then washing the plate (once or repeatedly) with water or a buffer. Typically, the polypeptide is contained in water or a buffer. The plate is then washed with a buffer that lacks the bound polypeptide. To block the free protein-binding sites on the plates, the plates are blocked with a protein that is unrelated to the bound polypeptide. For example, 300  $\mu\text{l}$  of bovine serum albumin (BSA) at a concentration of 2 mg/ml in Tris-HCl is suitable. Suitable substrates include those substrates that contain a defined cross-linking chemistry (e.g., plastic substrates, such as polystyrene, styrene, or polypropylene substrates from Corning Costar Corp. (Cambridge, MA), for example) . If desired, a beaded particle, e.g., beaded agarose or beaded sepharose, can be used as the substrate.

Binding of the test compound to the polypeptides according to the invention can be detected by any of a variety of artknown methods. For example, a specific antibody can be used in an immunoassay. If desired, the antibody can be labeled (e.g., fluorescently or with a radioisotope) and detected directly (see, e.g., West and McMahon, J. Cell Biol. 74:264, 1977). Alternatively, a second antibody can be used for detection (e.g., a labeled antibody that binds the Fc portion of an anti-AN97 antibody). In an alternative detection method, the

PEC38 polypeptide is labeled, and the label is detected (e.g., by labeling aPEC38 polypeptide with a radioisotope, fluorophore, chromophore, or the like). In still another method, the PEC38 polypeptide is produced as a fusion protein with a protein that can be detected optically, e.g., green fluorescent protein (which can be detected under UV light). In an alternative method, the PEC38 polypeptide can be covalently attached to or fused with an enzyme having a detectable enzymatic activity, such as horse radish peroxidase, alkaline phosphatase, a-galactosidase, or glucose oxidase. Genes encoding all of these enzymes have been cloned and are readily available for use by those of skill in the art. If desired, the fusion protein can include an antigen, and such an antigen can be detected and measured with a polyclonal or monoclonal antibody using conventional methods. Suitable antigens include enzymes (e.g., horse radish peroxidase, alkaline phosphatase, and a-galactosidase) and non-enzymatic polypeptides (e.g., serum proteins, such as BSA and globulins, and milk proteins, such as caseins).

#### **Epitopes, antigens and immunogens.**

In another aspect, the invention provides a peptide or polypeptide comprising an epitope-bearing portion of a polypeptide of the invention. The epitope of this polypeptide portion is an immunogenic or antigenic epitope of a polypeptide of the invention. An "immunogenic epitope" is defined as a part of a protein that elicits an antibody response when the whole protein is the immunogen. These immunogenic epitopes are believed to be confined to a few loci on the molecule. On the other hand, a region of a protein molecule to which an antibody can bind is defined as an "antigenic epitope." The number of immunogenic epitopes of a protein generally is less than the number of antigenic epitopes. See, for instance, Geysen, H. M. et al., Proc. Natl. Acad. Sci. USA 81:3998-4002 (1984).

As to the selection of peptides or polypeptides bearing an antigenic epitope (i.e., that contain a region of a protein molecule to which an antibody can bind), it is well known in that art that relatively short synthetic peptides that mimic part of a protein sequence are routinely capable of eliciting an antiserum that reacts with the partially mimicked protein. See, for instance, Sutcliffe, J. G. et al., Science 219:660-666 (1984). Peptides capable of eliciting protein-reactive sera are frequently represented in the primary sequence of a protein, can be characterized by a set of simple chemical rules, and are confined

neither to immunodominant regions of intact proteins (i.e., immunogenic epitopes) nor to the amino or carboxyl terminals. Peptides that are extremely hydrophobic and those of six or fewer residues generally are ineffective at inducing antibodies that bind to the mimicked protein; longer, soluble peptides, especially those

5 containing proline residues, usually are effective. Sutcliffe et al., *supra*, at 661. For instance, 18 of 20 peptides designed according to these guidelines, containing 8-39 residues covering 75% of the sequence of the influenza virus hemagglutinin HAI polypeptide chain, induced antibodies that reacted with the HA1 protein or intact virus; and 12/12 peptides from the MuLV polymerase and 18/18 from the  
10 rabies glycoprotein induced antibodies that precipitated the respective proteins.

Antigenic epitope-bearing peptides and polypeptides of the invention are therefore useful to raise antibodies, including monoclonal antibodies, that bind specifically to a polypeptide of the invention. Thus, a high proportion of hybridomas obtained by fusion of spleen cells from donors immunized with an  
15 antigen epitope-bearing peptide generally secrete antibody reactive with the native protein. Sutcliffe et al., *supra*, at 663. The antibodies raised by antigenic epitope bearing peptides or polypeptides are useful to detect the mimicked protein, and antibodies to different peptides may be used for tracking the fate of various regions of a protein precursor which undergoes posttranslation  
20 processing. The peptides and anti-peptide antibodies may be used in a variety of qualitative or quantitative assays for the mimicked protein, for instance in competition assays since it has been shown that even short peptides (e.g., about 9 amino acids) can bind and displace the larger peptides in immunoprecipitation assays. See, for instance, Wilson, I.A. et al., *Cell* 37:767-778 at 777 (1984). The  
25 anti-peptide antibodies of the invention also are useful for purification of the mimicked protein, for instance, by adsorption chromatography using methods well known in the art.

Antigenic epitope-bearing peptides and polypeptides of the invention designed according to the above guidelines preferably contain a  
30 sequence of at least seven, more preferably at least nine and most preferably between about 15 to about 30 amino acids contained within the amino acid sequence of a polypeptide of the invention. However, peptides or polypeptides comprising a larger portion of an amino acid sequence of a polypeptide of the invention, containing about 30 to about 50 amino acids, or any length up to and  
35 including the entire amino acid sequence of a polypeptide of the invention, also are considered epitope-bearing peptides or polypeptides of the invention and also

are useful for inducing antibodies that react with the mimicked protein. Preferably, the amino acid sequence of the epitope-bearing peptide is selected to provide substantial solubility in aqueous solvents (i.e., the sequence includes relatively hydrophilic residues and highly hydrophobic sequences are preferably avoided);  
5 and sequences containing proline residues are particularly preferred.

The epitope-bearing peptides and polypeptides of the invention may be produced by any conventional means for making peptides or polypeptides including recombinant means using nucleic acid molecules of the invention. For instance, a short epitope-bearing amino acid sequence may be fused to a larger  
10 polypeptide which acts as a carrier during recombinant production and purification, as well as during immunization to produce anti-peptide antibodies.

Epitope-bearing peptides also may be synthesized using known methods of chemical synthesis. For instance, Houghten has described a simple method for synthesis of large numbers of peptides, such as 10-20 mg of 248  
15 different 13 residue peptides representing single amino acid variants of a segment of the HAI polypeptide which were prepared and characterized (by ELISA-type binding studies) in less than four weeks. Houghten, R. A., Proc. Natl. Acad. Sci. USA 82:5131-5135 (1985). This "Simultaneous Multiple Peptide Synthesis (SMPS)" process is further described in U.S. Patent No. 4,631,211 to Houghten et  
20 al. (1986). In this procedure the individual resins for the solid-phase synthesis of various peptides are contained in separate solvent-permeable packets, enabling the optimal use of the many identical repetitive steps involved in solid-phase methods.

A completely manual procedure allows 500-1000 or more  
25 syntheses to be conducted simultaneously. Houghten et al., supra, at 5134.

Epitope-bearing peptides and polypeptides of the invention are used to induce antibodies according to methods well known in the art. See, for instance, Sutcliffe et al., supra; Wilson et al., supra; Chow, M. et al., Proc. Natl. Acad. Sci. USA 82:910-914; and Bittle, F.J. et al., J. Gen. Virol. 66:2347-2354  
30 (1985).

Generally, animals may be immunized with free peptide; however, anti-peptide antibody titer may be boosted by coupling of the peptide to a macromolecular carrier, such as keyhole limpet hemocyanin (KLH) or tetanus toxoid. For instance, peptides containing cysteine may be coupled to carrier using  
35 a linker such as maleimidobenzoyl-N-hydroxysuccinimide ester (MBS), while other peptides may be coupled to carrier using a more general linking agent such as

glutaraldehyde.

Animals such as rabbits, rats and mice are immunized with either free or carriercoupled peptides, for instance, by intraperitoneal and/or intradermal injection of emulsions containing about 100 ug peptide or carrier  
5 protein and Freund's adjuvant. Several booster injections may be needed, for instance, at intervals of about two weeks, to provide a useful titer of anti-peptide antibody which can be detected, for example, by ELISA assay using free peptide adsorbed to a solid surface. The titer of anti-peptide antibodies in serum from an immunized animal may be increased by selection of anti-peptide antibodies, for  
10 instance, by adsorption to the peptide on a solid support and elution of the selected antibodies according to methods well known in the art.

Immunogenic epitope-bearing peptides of the invention, i.e., those parts of a protein that elicit an antibody response when the whole protein is the immunogen, are identified according to methods known in the art. For  
15 instance, Geysen et al., 1984, supra, discloses a procedure for rapid concurrent synthesis on solid supports of hundreds of peptides of sufficient purity to react in an enzyme-linked immunosorbent assay. Interaction of synthesized peptides with antibodies is then easily detected without removing them from the support. In this manner a peptide bearing an immunogenic epitope of a desired protein may be  
20 identified routinely by one of ordinary skill in the art. For instance, the immunologically important epitope in the coat protein of foot-and-mouth disease virus was located by Geysen et al. with a resolution of seven amino acids by synthesis of an overlapping set of all 208 possible hexapeptides covering the entire 213 amino acid sequence of the protein. Then, a complete replacement set  
25 of peptides in which all 20 amino acids were substituted in turn at every position within the epitope were synthesized, and the particular amino acids conferring specificity for the reaction with antibody were determined. Thus, peptide analogs of the epitope-bearing peptides of the invention can be made routinely by this method. U.S. Patent No. 4,708,781 to Geysen (1987) further describes this  
30 method of identifying a peptide bearing an immunogenic epitope of a desired protein.

Further still, U.S. Patent No. 5,194,392 to Geysen (1990) describes a general method of detecting or determining the sequence of monomers (amino acids or other compounds) which is a topological equivalent of  
35 the epitope (i.e., a "mimotope") which is complementary to a particular paratope (antigen binding site) of an antibody of interest. More generally, U.S. Patent No.

4,433,092 to

Geysen (1989) describes a method of detecting or determining a sequence of monomers which is a topographical equivalent of a ligand which is complementary to the ligand binding site of a particular receptor of interest. Similarly, U.S. Patent  
5 No. 5,480,971 to Houghten, R. A. et al. (1996) on Peralkylated Oligopeptide Mixtures discloses linear C1-C7-alkyl peralkylated oligopeptides and sets and libraries of such peptides, as well as methods for using such oligopeptide sets and libraries for determining the sequence of a peralkylated oligopeptide that preferentially binds to an acceptor molecule of interest. Thus, non-peptide analogs  
10 of the epitope-bearing peptides of the invention also can be made routinely by these methods.

### **Use of PEC38 pectinases in industrial processes**

15 Pectins and pectinases play an important role in the food industry. Pectinases are used in the production of fruit and vegetable juices and purees, and in the extraction of useful components, like aroma compounds, or even pharmaceuticals, from plant materials.

One of the main application of pectinases is in the production of  
20 clear fruit and vegetable juice. The production of juices from fruit and vegetables typically involves, after an optional washing step, grinding, crushing or otherwise destroying the integrity of the fruit or vegetables thus obtaining a fruit or vegetable pulp. Subsequently, the pulp may be treated with enzymes to decrease soluble pectin, a process generally referred to as maceration. After maceration, the pulp is  
25 ready for pressing, leading to a juice fraction and a residue fraction, the latter being referred to as the pomace. The juice obtained after pressing is usually pasteurised, optionally with recovery of the aroma, which may then be added back at the end of the process. In order to obtain a clear concentrate, the pasteurised juice is enzymatically depectinized with the aid of pectinases, optionally pre-  
30 concentrated, filtrated, optionally ultra-filtrated and concentrated to obtain a clear concentrate or juice which is ready for shipping and/or blending to obtain a clear apple juice for the consumer market

PEC38 pectinases are useful in all production processes in which the integrity of the cell wall should be destroyed in order to release  
35 materials from the inside of the cells, or from the cell walls.

Pectinases can also be used to destroy the connection between cells without affecting the integrity of the separate cells. When cells should remain



intact, e.g. in the preparation of potato puree PEC38 pectinases can be used to release the structural connection between the cells.

PEC38 pectinases are also able to decrease the water-binding and hence the viscosity of pectin-containing slurries, e.g. fruit or vegetable pulps, which improves the pressability/processability of the pulp.

PEC38 pectinases are able to clarify cloudy juices. Attacking the outer pectin layer of the cloud particles changes the charge of the particles, thus promoting the aggregation of the particles.

PEC38 pectinases may also be used in the retting of flax (to release the cellulose fibres from the plant tissue) and the scouring of cotton (to increase the water absorbance and dye uptake of the cotton fibres).

Plant and pectin-containing materials include plant pulp, parts of plants and plant extracts. In the context of this invention an extract from a plant material is any substance which can be derived from plant material by extraction (mechanical and/or chemical), processing or by other separation techniques. The extract may be juice, nectar, base, or concentrates made thereof. The plant material may comprise or be derived from vegetables, e.g., carrots, celery, onions, legumes or leguminous plants (soy, soybean, peas) or fruit, e.g., pome or seed fruit (apples, pears, quince etc.), grapes, tomatoes, citrus (orange, lemon, lime, mandarin), melons, prunes, cherries, black currants, redcurrants, raspberries, strawberries, cranberries, pineapple and other tropical fruits, trees and parts thereof (e.g. pollen, from pine trees).

Fruit juice that needs to be filtrated after or during processing tends to clot the filters after some time. This is due to the inability of certain enzymes to properly digest fruit polysaccharides which causes the fouling of the filters.. Use of the enzymes according to the invention prevents fouling of filters because of the unique specificity of the PEC38 pectinase.

PEC38 pectinases may conveniently be produced in microorganisms. Microbial pectinases are available from a variety of sources; Bacillus spec. are a common source of bacterial enzymes, whereas fungal enzymes are commonly produced in Aspergillus spec.

In the above processes, it is advantageous to use pectinases that are obtained by recombinant DNA techniques. Such recombinant enzymes have a number of advantages over their traditionally purified counterparts. Recombinant enzymes may be produced at a low cost price, high yield, free from contaminating agents like bacteria or viruses but also free from bacterial toxins or

contaminating other enzyme activities.

The polypeptides of the invention may be used to treat plant material including plant pulp and plant extracts. For example, they may be used to treat apple pulp and/or raw juice during the production of apple juice. They may also be used to treat liquid or solid foodstuffs or edible foodstuff ingredients. Conveniently the polypeptide of the invention is combined with suitable (solid or liquid) carriers or diluents including buffers to produce a composition or enzyme preparation. The polypeptide is typically stably formulated either in liquid or dry form. Typically, the product is made as a composition which will optionally include, for example, a stabilising buffer and/or preservative. The compositions may also include other enzymes capable of digesting plant material or pectin, for example other pectinases such as an endo-arabinanase, rhamnogalacturonases, and/or polygalacturonase. For certain applications, immobilization of the enzyme on a solid matrix or incorporation on or into solid carrier particles may be preferred. The composition may also include a variety of other plant material-degrading enzymes, for example cellulases and other pectinases.

The polypeptides and compositions of the invention may therefore be used in a method of processing plant material to degrade or modify the pectin constituents of the cell walls of the plant material

Typically, the polypeptides of the invention are used as a composition/ enzyme preparation as described above. The composition will generally be added to plant pulp obtainable by, for example mechanical processing such as crushing or milling plant material. Incubation of the composition with the plant will typically be carried out for a time of from 10 minutes to 5 hours, such as 30 minutes to 2 hours, preferably for about 1 hour. The processing temperature is preferably 10-55°C, e.g. from 15 to 25°C, optimally about 20°C and one can use 10-300g, preferably 30-70g, optimally about 50g of enzyme per ton of material to be treated. All the enzyme(s) or their compositions used may be added sequentially or at the same time to the plant pulp. Depending on the composition of the enzyme preparation the plant material may first be macerated (e.g. to a purée) or liquefied. Using the polypeptides of the invention processing parameters such as the yield of the extraction, viscosity of the extract and/or quality of the extract can be improved.

Alternatively, or in addition to the above, a polypeptide of the invention may be added to the raw juice obtained from pressing or liquefying the

plant pulp. Treatment of the raw juice may be carried out in a similar manner to the plant pulp in respect of dosage, temperature and holding time. Again, other enzymes than pectinases may be included.

5 A composition containing a polypeptide of the invention may also be used during the preparation of fruit or vegetable purees. The end product of these processes is typically heat-treated at 85°C for a time of from 1 minute to 1 hour, under conditions to partially or fully inactivate the polypeptides of the invention.

10 Due to the highly specific action on pectins the polypeptides of the invention may also be used to prepare pectins with modified characteristics, e.g. modified gelation capacities for specific applications.

The polypeptides of the invention may be added to animal feeds rich in pectin, e.g. soy-containing food, to improve the breakdown of the plant cell wall leading to improved utilisation of the plant nutrients by the animal. The  
15 polypeptides of the invention may be added to the feed or silage if pre-soaking or wet diets are preferred. Advantageously, the polypeptides of the invention may continue to degrade pectins in the feed in vivo. Fungal derived polypeptides of the invention in particular generally have lower pH optima and are capable of releasing important nutrients in such acidic environments as the stomach of an  
20 animal. The invention thus also contemplates (e.g. animal) feeds or foodstuffs comprising one or more polypeptides of the invention.

A PEC38 pectinase may also be advantageously used during the production of milk substitutes (or replacers) from soy bean. These milk substitutes can be consumed by both humans and animals. A typical problem  
25 during the preparation of these milk substitutes is the high viscosity of the soy bean slurry, resulting in the need for an undesirable dilution of the slurry to a concentration of dry solids of 10 to 15%. An enzyme preparation containing a polypeptide of the invention can be added to, or during the processing of, the slurry, enabling processing at a higher concentration (typically 40 to 50%) dry  
30 solids. Addition of pectinases of the invention to a soy suspension as described in WO 95/29598 results in a decrease in waterbinding and a concomitant decrease in viscosity of the slurry.

The enzyme may also be used in the preparation of savoury product(s), e.g. from soy bean.

35 The invention also relates to the use of the PEC38 pectinase according to the invention in a selected number of industrial and pharmaceutical

processes. Despite the long term experience obtained with these processes, the pectinase according to the invention features a number of significant advantages over the enzymes currently used. Depending on the specific application, these advantages can include aspects like lower production costs, higher specificity  
5 towards the substrate, less antigenic, less undesirable side activities, higher yields when produced in a suitable microorganism, more suitable pH and temperature ranges, better tastes of the final product as well as food grade and kosher aspects.

An important aspect of the pectinases according to the invention  
10 is that they cover a whole range of pH and temperature optima which are ideally suited for a variety of applications. For example many large scale processes benefit from relatively high processing temperatures of 50 degrees C or higher, e.g. to control the risks of microbial infections. Several pectinases according to the invention comply with this demand but at the same time they are not that heat  
15 stable that they resist attempts to inactivate the enzyme by an additional heat treatment. The latter feature allows production routes that yield final products free of residual enzyme activity. Similarly many feed and food products have slightly acidic pH values so that pectinases with acidic or near neutral pH optima are preferred for their processing. A PEC38 pectinase according to the invention  
20 complies with this requirement as well.

The polypeptides of the invention may also be added to animal feeds rich in pectin or xylogalacturonan, to reduce anti-nutritional effects of plant pectins and consequently improve production performances and welfare of the animals, as well reducing environmental pollution.

25 It has been shown that plant pectins increase digesta viscosity, fermentation and colonisation of bacterial proliferation in the gastro intestinal tract (Langhout, D.J. (1998). The role of the intestinal flora as affected by non-starch polysaccharides in broiler chicks. PhD thesis, Agricultural University Wageningen, The Netherlands). As a consequence, several digestive physiological parameters  
30 are altered (Johnson, I.T. and Gee, J.M. (1981). Effect of gel-forming gums on the intestinal unstirred layer and sugar transport in vitro. Gut 22:398-403. Johnson, I.T. and Gee, J.M. (1986). Gastrointestinal adaption in response to soluble non-available polysaccharides in the rat. British Journal of Nutrition 55:497-505, Johnson, I.T. , Gee, J.M. and Mahoney, R.R. (1984). Effect of dietary  
35 supplements of guar gum or cellulose on intestinal cell proliferation, enzyme levels and glucose transport in the rat. British Journal of Nutrition 52:477-487) resulting

in reduced dietary nutrient, mineral and energy utilization (Langhout, D.J. and Schutte, J.B. (1996). Nutritional implications of pectins in chicks in relation to esterification and origin of pectins. *Poultry Science* 75:1236-1242, Smits, C.M.H., Veldman, A., Verkade, H.J. and Beynen, A.C. (1998). The inhibitory effect of

5 carboxymethylcellulose with high viscosity on lipid absorption in broiler chickens coincides with reduced bile salt concentration and raised microbial numbers in the small intestine. *Poultry Science* 77:1534-1539). The magnitude efficiency of dietary nutrient utilization is reduced, the effectivity in production performances (e.g. efficiency of producing milk, eggs, wool and meat) declines. Moreover, at

10 reduced dietary nutrient utilization by the animal, excretion of and environmental pollution with e.g. nitrogenous compounds and heavy metals is increased.

Advantageous is that these fungal derived polypeptides of the invention have generally lower pH optima and their activities are therefore (more) capable of hydrolysis in such acidic environments as the stomach of an animal.

15 With that, anti-nutritional properties of the plant cell wall fractions are already reduced early on in the digestive tract of the animal.

## **ABSTRACT**

The invention relates to newly identified polynucleotide sequences comprising genes that encode novel pectinases isolated from *Aspergillus niger*. The invention features the full length nucleotide sequence of the novel gene, the cDNA sequence comprising the full length coding sequence of the novel pectinase as well as the amino acid sequence of the full-length functional protein and functional equivalents thereof. The invention also relates to methods of using these enzymes in industrial processes and methods of diagnosing fungal infections. Also included in the invention are cells transformed with a polynucleotide according to the invention and cells wherein an pectinase according to the invention is genetically modified to enhance or reduce its activity and/or level of expression.

## **CLAIMS**

- 1) An isolated polynucleotide hybridisable to a polynucleotide according to SEQ ID NO:1 or SEQ ID NO: 2
- 2) An isolated polynucleotide according to claim 1 hybridisable under high stringency conditions to a polynucleotide according to SEQ ID NO:1 or SEQ ID NO: 2
- 3) An isolated polynucleotide according to claims 1 or 2 obtainable from a filamentous fungus.
- 4) An isolated polynucleotide according to claim 3 obtainable from *A. niger*.
- 5) An isolated polynucleotide encoding a polypeptide comprising an amino acid sequence according to SEQ ID NO: 3 or functional equivalents thereof.
- 6) An isolated polynucleotide encoding at least one functional domain of a polypeptide according to SEQ ID NO: 3 or functional equivalents thereof.
- 7) An isolated polynucleotide comprising a nucleotide sequence according to SEQ ID NO: 1 or SEQ ID NO: 2 or functional equivalents thereof
- 8) An isolated polynucleotide according to SEQ ID NO: 1 or SEQ ID NO: 2.
- 9) A vector comprising a polynucleotide sequence according to claims 1 to 8.
- 10) A vector according to claim 9 wherein said polynucleotide sequence according to claims 1 to 8 is operatively linked with regulatory sequences suitable for expression of said polynucleotide sequence in a suitable host cell.
- 11) A vector according to claim 10 wherein said suitable host cell is a filamentous fungus
- 12) A method for manufacturing a polynucleotide according to claims 1 – 8 or a vector according to claims 9 to 11 comprising the steps of culturing a host cell transformed with said polynucleotide or said vector and isolating said polynucleotide or said vector from said host cell.
- 13) An isolated polypeptide according to SEQ ID NO: 3 or functional equivalents thereof.
- 14) An isolated polypeptide according to claim 13 obtainable from *Aspergillus niger*
- 15) An isolated polypeptide obtainable by expressing a polynucleotide according to claims 1 to 8 or a vector according to claims 9 to 11 in an appropriate host cell, e.g. *Aspergillus niger*.
- 16) Recombinant pectinase comprising a functional domain of a PEC38 polypeptide.

- 17) A method for manufacturing a polypeptide according to claims 13 to 16 comprising the steps of transforming a suitable host cell with an isolated polynucleotide according to claims 1 to 8 or a vector according to claims 9 to 11, culturing said cell under conditions allowing expression of said polynucleotide and optionally purifying the encoded polypeptide from said cell or culture medium.
- 18) A recombinant host cell comprising a polynucleotide according to claims 1 to 8 or a vector according to claims 9 to 11.
- 19) A recombinant host cell expressing a polypeptide according to claims 13 to 16.
- 20) Purified antibodies reactive with a polypeptide according to claims 13 to 16.
- 21) Fusion protein comprising a polypeptide sequence according to claims 13 to 16.



# SEQUENCE LISTING

<110> DSM NV.

<120> Novel pectinase PEC38 and uses thereof

<130> 20797EP/P0

<160> 3

<170> XML to WIPO ST.25 Converter - <http://www.biomax.de/>

<210> 1

<211> 5697

<212> DNA

<213> *Aspergillus niger*

<400> 1

cgctgtggga	atatgagaag	atcgctaatt	agggtggattg	tcacacaggc	gcaatgagct	60
ggcagacagc	tgtgtttgtgt	agaaccgcag	ccggtcgtct	ccgcaactcc	gccgacgac	120
aaaagcagat	cagtgccagg	caacgataaa	ctcaagatgc	gatatgtata	tcgtgtcaag	180
atccgttttcg	ccagaagttt	tgtcagcgat	ttcgcatagc	tagcagttct	gtgcgatcgt	240
gccactgcaa	ggtttttaggg	ggggttttcg	taagaaaagc	gtcaagactc	cggggccgcg	300
cggtcgcgtgt	ggctcgtgggt	agataggcgc	cgtgaacgaa	agaacaacaa	ttgattgggg	360
gtgattgccg	ggctgtcttg	cagattgagg	ggggcgcttg	gaggctagca	gcagatcaag	420
tcaagagcag	cagagcagac	aaaggccagc	tgggtgctgga	ggaggaggag	gagccggcga	480
agaaaaagaa	ggttgagctt	aaggctaagc	agcagcagtg	gagccgagag	tgacgacggc	540
gaaagagaag	ttgtttgggtg	cgtcagaacg	gcgggcgctt	cggtgataa	gcatttgacc	600
attccaccct	tgccgtctag	aatgttgacg	ttattccaca	ccgtgcagga	gaatatttcc	660
tggacgctaa	gctataccac	aaggaaggaa	ttgaatgctt	ttatgtgatc	aaatgaacct	720
tcagggaactg	cagttctgca	ttataagttc	cgatccagga	aacgcgtcgc	taaaaattgc	780
tggatggctg	tggagagtcc	agtgcctacg	acgttggcat	ccacaccctc	gttcgtctgc	840
atccgcaaca	ggagatgac	gtctaagcct	tgtcagattg	attaactgct	tactcgtctg	900
aagtgtcttcg	gtctgcagtt	cccttggcac	gatggtttgt	ctcaaagaga	tgccgggatgg	960
tgggtgctgcc	gataaacttc	ccatccgagg	tggatatcgt	ttcgcttccc	cacaaatcgg	1020
gcagtggtgg	tgggtgccgtt	tgcagccaaa	tgtcgccttg	atcgcaacga	atttagaaac	1080
catgccagggt	ccactacatg	gtctagatct	aagcagtcct	tgctgcaatt	aggttacttc	1140
tacctccagg	cgaccctttt	tgggtaaaaag	ggttcttgct	ttcgcatcaa	tctctactaa	1200
gacatcgtgt	ccccattcgc	atcgaagtca	agcctgaggg	gcacccactc	agcccatccg	1260
aagaagacgc	ggtttacgta	gcctggaggg	tggacactgc	gtcagccccg	tgaagccgcg	1320
tcatacgtcg	agccggctgc	tgcaccccg	acttcttggc	tccggcgctt	agtagatgac	1380
cttttgtagc	aagtgttttg	gtgaccgttc	ggcgtgatag	tgacaggtga	aagccaccta	1440
cattgcttga	cctgcacggc	tcgtccactt	acagggcgcg	ggccagggcc	aagcaacaac	1500
caactgcagct	atcattggct	cgatattcct	ccaccgctcg	ccatgtcaac	cgactgagta	1560
gcaccgtaca	aacctcttac	tatcacagta	tcacgttggc	tcatatgggtg	atctgcagtc	1620
acgctatact	attcgtggct	ttgctaacaa	cactgtcaag	tttgacaatt	cacctattgc	1680
gcagaaaagc	acgcacatat	cttcctctct	acaggtgtaa	cttgttctat	ggtactccag	1740
gggttgtgggt	gaggaaaaag	tccagattcg	cctttcctct	ctgcggtcac	gtgcgacacg	1800
tggaaacctcc	ccaggcggtg	aatggctctt	tgcggcctca	cagacccgct	ccataccaga	1860
tacagctaga	cgcactgccg	ggccttggat	gggttccttg	gaccttgaga	aacaattccc	1920
accgttggat	gttacagtcg	ctgaaccact	acagggactt	tcagcagatg	aaaccttaca	1980
accaggtttc	tcattccaaag	gaacacggaa	acgagctgtg	gttgtaggtg	gcttgttttc	2040
aatccaggggt	actggtcgtc	atcaatagaa	gcaccttgag	gtagagtgtg	tatgcattca	2100
caattgtagt	ctcaactgga	atgcacacat	cccggctact	cattgtcaaa	catacgaggt	2160
gggtgttcta	tcctctcctg	ctctactcta	ctacaccaca	actccataaa	tgtaaactta	2220
cggactcaga	aatgttgaca	agccagccgc	tgaggtaagc	aggggatcgt	gcggatctgg	2280

atctctcaga	atgacgaaca	ggaacttgac	atctccgacg	ctgttggcag	tggtgatcg	2340
tcccgtccat	tcacatctta	ggaatggtca	gacaggacaa	gtcgccctcg	gcctgtttca	2400
caatgacttg	cgtgcttttag	cccaaactgt	cctcaccgtc	gtgcctatca	tcacttacct	2460
agtcttcttg	aagtgtcat	ccactctccc	catgagccgt	tatcactgac	cctcaaaacc	2520
ctgtacctat	tttccacca	tggtcacct	cattggtca	gtacactgac	tcctcaaccc	2580
tctcccttaa	ccaccaaa	cagagtagta	aatgacaccc	tccagtctga	agactattcc	2640
ctggttcgcg	cgcgcggatg	gcaacatccc	agaaagtaca	ttcaggtgga	taccatgaaa	2700
ggcctcccg	cactgctgaa	cagcagcagc	acaaaaaat	ggacacaatc	caccccatcc	2760
acaggcgagg	gtgagaatga	gagtggtagt	actatatcac	ccaccaagcc	gcccagacca	2820
tccacacccc	caggaggctc	aaacacctcc	atgatctgga	cgcggaagaa	gataatatgg	2880
ctcatcacc	tgatagctct	aagcgtagcc	ataatcgtgg	tggtgataac	cgtcccagta	2940
gttctcctgc	tggacgataa	acacaacgac	gatcccagct	actacaacag	cgccaaccgt	3000
ccagtccgcg	tcgtgcatga	cttccccgac	ccgggtctaa	tccaggtgaa	cagcacgtgg	3060
tatgcatacg	ctacagtcgc	cacaccggac	aatcctgacg	tcctcacgt	cccggtatcg	3120
acatcgcgga	acttttagcag	ctggacctgg	ttgcagggat	acgatgttat	gcctgcaatt	3180
agcagttggg	aaacgaatat	gaaccagtac	gtccggagcg	tgattcaacg	cgtaagtact	3240
agcccaacca	tcaagcataa	ccaaatcaac	taaataccct	tatagaaaaga	cggccaacttc	3300
gtcctctact	actcaggcga	actaaaagac	tggtccgcgc	accactgcgt	cggcgccgct	3360
gtctccaacg	gcacaagtcc	cctaggacca	tacatccccc	acaacaccac	cctcgcttgt	3420
ccccgcgacc	acggcggtgc	catcgacccc	gcccccttca	gagacgtcaa	cgggaccctc	3480
tacgtcgtgt	acaaagtcga	cggcaacagc	atcggccacg	gcgaggctg	caacaacggc	3540
aagaaacca	tcgtctccac	gcccacatg	ctccaacaac	tcaaagacga	tggagtcacc	3600
cccgtcgggtg	atcccgttga	aattctaacc	aacgaaaaag	tcgatgggcc	gttagtcgag	3660
gctccggcca	ttattcgaac	tgatcgcggc	atctattatc	tgttcttctc	ttcgattgc	3720
tttacatcgt	cgaagtatag	tgtaaagtat	gcatggtcaa	catcgttaaa	ggggccgtat	3780
accagggctg	agaggccctt	gttccgggtc	ggggactttg	ggctaaagtc	tcctggcggt	3840
gcgacggctt	cgttgatgg	gtctaggatt	gtttttcatg	ccttttgtgg	ggattataga	3900
tgtatgtatg	ccgcggcgat	gaatattacg	gctaattata	cgattttgcc	ggcgcgctt	3960
tgaggttgga	ttggattata	gatttggttg	tggtgttgtt	gtgtgagata	gactagagtc	4020
tgagtctgta	cataattttg	ataaaaagtta	tagaccttat	ctttcatgca	ctaggtagag	4080
tttcaggga	gccatcaata	ctatcctagg	ttcggttact	ccaagtcaaa	cactcatatt	4140
cctccgatga	ccaagaataa	agcagaagca	agacagccct	cagattagct	ctcaggttct	4200
caccgggtttc	caggcagata	atggtaggga	cttgtgcatt	ctcgacaag	tcgtgccgga	4260
taccatgcaa	atttggcttt	tgatttcatg	attcgtcact	gggtgtctg	cttgcttgct	4320
ccatctcttg	tccatatcat	tgacttcaat	accogtgtat	gtttgtcttg	cgtcattagc	4380
tgtattgggt	atgcattcac	atgaacctgt	ttatcataac	acaacataat	gcaacatcca	4440
tatcattaca	tgaatagtag	cataatctca	atgcggtcga	catgaggttg	tgattagtag	4500
acataatact	gatttgaaaa	cattgagcaa	tgttaaaggt	agtctggcac	ggcacgttgg	4560
cacggcacgt	tgtactcaac	atggaggaaa	agggcgaggt	gataaagggg	gagaggataa	4620
gaccgccatc	agattgaaaa	ctaccgttta	tacatcactc	ttcactgacg	tgctcgacat	4680
cgttatcttt	gtcagaaaca	gatggagcaa	tatgagagtc	tcggagtaaa	gtgctagatt	4740
tctttatcat	cattgggggc	gttggcacag	aacaagcaga	ggagcaatgt	ggttgtgcaa	4800
aagtaacaga	gttgatcagt	gcggaaaata	aaaagaataa	gatcagtaga	agaaggggtat	4860
gtggtcagta	atatgaaaat	gaaaaaagtg	agttgagcaa	accaaggcta	taccogaaca	4920
ttagaggata	agtcctgtc	ataagtactt	attgaaggaa	gaaaaaggaa	tcatccaaac	4980
agaatgagca	acttttgtaa	tctcttagat	ctctgttcag	tctcaatcat	ccaogcttgg	5040
tcagatgtct	tcttccattc	gggatccga	aggatgaagt	ccactgcctg	atltgaatca	5100
taagggtgtc	atgagaaagc	tctttgtgtg	tggttatcgt	cattgagatt	ggaaagcgct	5160
attcatagaa	gtaagaaatc	cagctatgaa	taaggcaag	gttgcgagac	gcgacctatc	5220
ttctagatat	tacatgtgg	gtgttgcttc	gcggaacagc	gcgtttttgt	ggtcgacgcg	5280
gagagcacgt	gaccgattct	tatgcagttt	ggtatlttgcg	caatltttaca	tgctgactaa	5340
ggatattgca	cataatatgc	tcgatttgct	gccccaatc	gctatacggc	cataagtcct	5400
aaacagtgtc	cagcatcgat	accttaacca	agggcattga	taccggctgt	gttgctggca	5460
gaaagttcac	cataattatg	atcaccctt	tagagaacag	aacatcatcc	aggtcagggtg	5520
taaccatcca	tagagggtata	tctttctttc	atatgatgta	cactgtacta	tactataatt	5580
catctcatgg	ttaccaatat	atctttgctt	tctatatagt	ccaaatgcct	gaattcatct	5640
ctataccaaa	tccatatatg	cttatcccac	caatatatcc	acttaaatag	tactcaa	5697

<210> 2  
 <211> 1485  
 <212> DNA  
 <213> *Aspergillus niger*

<220>  
 <221> CDS  
 <222> (1) .. (1485)

<400> 2  
 atg ttg aca agc cag ccg ctg agc cca aac tgt cct cac cgt cgt gcc 48  
 Met Leu Thr Ser Gln Pro Leu Ser Pro Asn Cys Pro His Arg Arg Ala  
 1 5 10 15  
 tat cat cac tta cct agt ctt ctt gaa gtg ctc atc cac tct ccc cat 96  
 Tyr His His Leu Pro Ser Leu Leu Glu Val Leu Ile His Ser Pro His  
 20 25 30  
 gag ccg tta tca ctg acc ctc aaa acc ctg tac cta ttt tcc acc aat 144  
 Glu Pro Leu Ser Leu Thr Leu Lys Thr Leu Tyr Leu Phe Ser Thr Asn  
 35 40 45  
 ggc tca cct cat tgg ctc agc tac ctg act cct caa ccc tct ccc tta 192  
 Gly Ser Pro His Trp Leu Ser Tyr Leu Thr Pro Gln Pro Ser Pro Leu  
 50 55 60  
 acc acc aaa cac aga gta gta aat gac acc ctc cag tct gaa gac tat 240  
 Thr Thr Lys His Arg Val Val Asn Asp Thr Leu Gln Ser Glu Asp Tyr  
 65 70 75 80  
 tcc ctg gtt cgc gcg cgc gga tgg caa cat ccc aga aag tac att cag 288  
 Ser Leu Val Arg Ala Arg Gly Trp Gln His Pro Arg Lys Tyr Ile Gln  
 85 90 95  
 gtg gat acc atg aaa ggc ctc ccg tca ctg ctg aac agc agc agc acc 336  
 Val Asp Thr Met Lys Gly Leu Pro Ser Leu Leu Asn Ser Ser Ser Thr  
 100 105 110  
 aaa aaa tgg aca caa tcc acc cca tcc aca ggc gag ggt gag aat gag 384  
 Lys Lys Trp Thr Gln Ser Thr Pro Ser Thr Gly Glu Gly Glu Asn Glu  
 115 120 125  
 agt ggt agt act ata tca ccc acc aag ccg ccc gag cca tcc aca ccc 432  
 Ser Gly Ser Thr Ile Ser Pro Thr Lys Pro Pro Glu Pro Ser Thr Pro  
 130 135 140  
 cca gga ggc tca aac acc tcc atg atc tgg acg cgg aag aag ata ata 480  
 Pro Gly Gly Ser Asn Thr Ser Met Ile Trp Thr Arg Lys Lys Ile Ile  
 145 150 155 160  
 tgg ctc atc acc ctg ata gct cta agc gta gcc ata atc gtg gtg gtg 528  
 Trp Leu Ile Thr Leu Ile Ala Leu Ser Val Ala Ile Ile Val Val Val  
 165 170 175  
 ata acc gtc cca gta gtt ctc ctg ctg gac gat aaa cac aac gac gat 576  
 Ile Thr Val Pro Val Val Leu Leu Leu Asp Asp Lys His Asn Asp Asp  
 180 185 190  
 ccc agc tac tac aac agc gcc aac cgt cca gtc cgc gtc gtg cat gac 624  
 Pro Ser Tyr Tyr Asn Ser Ala Asn Arg Pro Val Arg Val Val His Asp  
 195 200 205  
 ttc ccc gac ccg ggt cta atc cag gtg aac agc acg tgg tat gca tac 672  
 Phe Pro Asp Pro Gly Leu Ile Gln Val Asn Ser Thr Trp Tyr Ala Tyr  
 210 215 220  
 gct aca gtc gcc aca ccg gac aat cct gac gtc cct cac gtc ccg gta 720  
 Ala Thr Val Ala Thr Pro Asp Asn Pro Asp Val Pro His Val Pro Val  
 225 230 235 240

tcg aca tcg cgg aac ttt agc agc tgg acc tgg ttg cag gga tac gat	768
Ser Thr Ser Arg Asn Phe Ser Ser Trp Thr Trp Leu Gln Gly Tyr Asp	
245 250 255	
gtt atg cct gca att agc agt tgg gaa acg aat atg aac cag tac gct	816
Val Met Pro Ala Ile Ser Ser Trp Glu Thr Asn Met Asn Gln Tyr Ala	
260 265 270	
ccg gac gtg att caa cgc aaa gac ggc cac ttc gtc ctc tac tac tca	864
Pro Asp Val Ile Gln Arg Lys Asp Gly His Phe Val Leu Tyr Tyr Ser	
275 280 285	
ggc gaa cta aaa gac tgg ctc cgc cac cac tgc gtc ggc gcc gct gtc	912
Gly Glu Leu Lys Asp Trp Leu Arg His His Cys Val Gly Ala Ala Val	
290 295 300	
tcc aac ggc aca agt ccc cta gga cca tac atc ccc cac aac acc acc	960
Ser Asn Gly Thr Ser Pro Leu Gly Pro Tyr Ile Pro His Asn Thr Thr	
305 310 315 320	
ctc gcc tgt ccc cgc gac cac ggc ggt gcc atc gac ccc gcc ccc ttc	1008
Leu Ala Cys Pro Arg Asp His Gly Gly Ala Ile Asp Pro Ala Pro Phe	
325 330 335	
aga gac gtc aac ggg acc ctc tac gtc gtg tac aaa gtc gac ggc aac	1056
Arg Asp Val Asn Gly Thr Leu Tyr Val Val Tyr Lys Val Asp Gly Asn	
340 345 350	
agc atc ggc cac ggc gga ggc tgc aac aac ggc aag aaa ccc atc gtc	1104
Ser Ile Gly His Gly Gly Gly Cys Asn Asn Gly Lys Lys Pro Ile Val	
355 360 365	
tcc acg ccc atc atg ctc caa ctc aaa gac gat gga gtc acc ccc	1152
Ser Thr Pro Ile Met Leu Gln Leu Lys Asp Asp Gly Val Thr Pro	
370 375 380	
gtc ggt gat ccc gtt gaa att cta acc aac gaa aaa gtc gat ggg ccg	1200
Val Gly Asp Pro Val Glu Ile Leu Thr Asn Glu Lys Val Asp Gly Pro	
385 390 395 400	
tta gtc gag gct ccg gcc att att cga act gat cgc ggc atc tat tat	1248
Leu Val Glu Ala Pro Ala Ile Ile Arg Thr Asp Arg Gly Ile Tyr Tyr	
405 410 415	
ctg ttc ttc tct tcg cat tgc ttt aca tcg tcg aag tat agt gtt aag	1296
Leu Phe Phe Ser Ser His Cys Phe Thr Ser Ser Lys Tyr Ser Val Lys	
420 425 430	
tat gca tgg tca aca tcg tta aag ggg ccg tat acc agg gct gag agg	1344
Tyr Ala Trp Ser Thr Ser Leu Lys Gly Pro Tyr Thr Arg Ala Glu Arg	
435 440 445	
ccc ttg ttc cgg tct ggg gac ttt ggg cta aag tct cct ggc ggt gcg	1392
Pro Leu Phe Arg Ser Gly Asp Phe Gly Leu Lys Ser Pro Gly Gly Ala	
450 455 460	
acg gct tcg gtt gat ggg tct agg att gtt ttt cat gcc ttt tgt ggg	1440
Thr Ala Ser Val Asp Gly Ser Arg Ile Val Phe His Ala Phe Cys Gly	
465 470 475 480	
gat tat aga tgt aga gtt tca ggg aag cca tca ata cta tcc tag	1485
Asp Tyr Arg Cys Arg Val Ser Gly Lys Pro Ser Ile Leu Ser	
485 490	

<210> 3

<211> 494

<212> PRT

<213> *Aspergillus niger*

<400> 3

Met Leu Thr Ser Gln Pro Leu Ser Pro Asn Cys Pro His Arg Arg Ala

1				5					10				15
Tyr	His	His	Leu	Pro	Ser	Leu	Leu	Glu	Val	Leu	Ile	His	Ser
			20					25					30
Glu	Pro	Leu	Ser	Leu	Thr	Leu	Lys	Thr	Leu	Tyr	Leu	Phe	Ser
		35					40					45	Thr
Gly	Ser	Pro	His	Trp	Leu	Ser	Tyr	Leu	Thr	Pro	Gln	Pro	Ser
		50				55					60		Pro
Thr	Thr	Lys	His	Arg	Val	Val	Asn	Asp	Thr	Leu	Gln	Ser	Glu
65				70					75				Asp
Ser	Leu	Val	Arg	Ala	Arg	Gly	Trp	Gln	His	Pro	Arg	Lys	Tyr
			85					90					Ile
Val	Asp	Thr	Met	Lys	Gly	Leu	Pro	Ser	Leu	Leu	Asn	Ser	Ser
			100					105					Thr
Lys	Lys	Trp	Thr	Gln	Ser	Thr	Pro	Ser	Thr	Gly	Glu	Gly	Glu
		115					120					125	Asn
Ser	Gly	Ser	Thr	Ile	Ser	Pro	Thr	Lys	Pro	Pro	Glu	Pro	Ser
		130				135					140		Thr
Pro	Gly	Gly	Ser	Asn	Thr	Ser	Met	Ile	Trp	Thr	Arg	Lys	Lys
145				150					155				Ile
Trp	Leu	Ile	Thr	Leu	Ile	Ala	Leu	Ser	Val	Ala	Ile	Ile	Val
			165						170				Val
Ile	Thr	Val	Pro	Val	Val	Leu	Leu	Leu	Asp	Asp	Lys	His	Asn
			180					185					Asp
Pro	Ser	Tyr	Tyr	Asn	Ser	Ala	Asn	Arg	Pro	Val	Arg	Val	Val
		195					200					205	His
Phe	Pro	Asp	Pro	Gly	Leu	Ile	Gln	Val	Asn	Ser	Thr	Trp	Tyr
		210				215						220	Ala
Ala	Thr	Val	Ala	Thr	Pro	Asp	Asn	Pro	Asp	Val	Pro	His	Val
225					230					235			Pro
Ser	Thr	Ser	Arg	Asn	Phe	Ser	Ser	Trp	Thr	Trp	Leu	Gln	Gly
			245						250				Tyr
Val	Met	Pro	Ala	Ile	Ser	Ser	Trp	Glu	Thr	Asn	Met	Asn	Gln
			260					265					Tyr
Pro	Asp	Val	Ile	Gln	Arg	Lys	Asp	Gly	His	Phe	Val	Leu	Tyr
		275					280					285	Tyr
Gly	Glu	Leu	Lys	Asp	Trp	Leu	Arg	His	His	Cys	Val	Gly	Ala
		290				295					300		Ala
Ser	Asn	Gly	Thr	Ser	Pro	Leu	Gly	Pro	Tyr	Ile	Pro	His	Asn
305					310					315			Thr
Leu	Ala	Cys	Pro	Arg	Asp	His	Gly	Gly	Ala	Ile	Asp	Pro	Ala
			325						330				Pro
Arg	Asp	Val	Asn	Gly	Thr	Leu	Tyr	Val	Val	Tyr	Lys	Val	Asp
			340					345					Gly
Ser	Ile	Gly	His	Gly	Gly	Gly	Cys	Asn	Asn	Gly	Lys	Lys	Pro
		355					360					365	Ile
Ser	Thr	Pro	Ile	Met	Leu	Gln	Gln	Leu	Lys	Asp	Asp	Gly	Val
		370				375						380	Thr
Val	Gly	Asp	Pro	Val	Glu	Ile	Leu	Thr	Asn	Glu	Lys	Val	Asp
385					390					395			Gly
Leu	Val	Glu	Ala	Pro	Ala	Ile	Ile	Arg	Thr	Asp	Arg	Gly	Ile
			405						410				Tyr
Leu	Phe	Phe	Ser	Ser	His	Cys	Phe	Thr	Ser	Ser	Lys	Tyr	Ser
			420					425					Val
Tyr	Ala	Trp	Ser	Thr	Ser	Leu	Lys	Gly	Pro	Tyr	Thr	Arg	Ala
		435					440					445	Glu
Pro	Leu	Phe	Arg	Ser	Gly	Asp	Phe	Gly	Leu	Lys	Ser	Pro	Gly
		450				455							Ala

Thr Ala Ser Val Asp Gly Ser Arg Ile Val Phe His Ala Phe Cys Gly  
465 470 475 480  
Asp Tyr Arg Cys Arg Val Ser Gly Lys Pro Ser Ile Leu Ser  
485 490

**PCT/EP2003/005726**

